![]() |
![]() |
![]() |
![]() |
3-P | NOVEL COPY NUMBER ALTERATIONS IN INFANTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL) | Marcela B. Mansur | ![]() |
![]() |
|||
6-P | ACUTE LYMPHOBLASTIC LEUKEMIA RECOGNITION BY NATURAL KILLER CELLS: CLINICAL AND THERAPEUTIC IMPLICATIONS | Nadia Peragine | ![]() |
![]() |
|||
7-P | K-RASG12D-initiated T-ALL development in mice is accompanied by loss of the wild-type Kras allele | Anna Staffas | ![]() |
![]() |
|||
8-P | FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF COPY NUMBER ALTERATIONS (CNA) IN HIGH-RISK B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS ENROLLED IN RISK-ADAPTED PROTOCOLS | Jordi Ribera | ![]() |
![]() |
|||
9-P | P38ALPHA/BETA INHIBITION PREVENTS ALL PROLIFERATION IN VIVO | Denis Schewe | ![]() |
![]() |
|||
12-P | ANALYSIS OF CRLF2 EXPRESSION IN A COHORT OF 91 NEWLY DIAGNOSED ADULT PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: CORRELATION WITH CLINICO-BIOLOGICAL FEATURES AND OUTCOME | Fulvia Brugnoletti | ![]() |
![]() |
|||
13-P | A CLINICALLY RELEVANT POPULATION OF LEUKEMIC CD34CD19CD58- CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Yuan Kong | ![]() |
![]() |
|||
17-P | ETV6/RUNX1 TRANSCRIPT IS A POTENTIAL TARGET OF RNA-BINDING PROTEIN IGF2BP1 | Mindaugas Stoskus | ![]() |
![]() |
|||
18-P | SNP ARRAY ANALYSIS OF ADULT ALL: A POPULATION BASED STUDY OF LITHUANIAN PATIENTS | Vaidas Dirse | ![]() |
![]() |
|||
22-P | PML/RAR-ALPHA INHIBITS PTEN EXPRESSION IN HEMATOPOIETIC CELLS BY COMPETING WITH PU.1 TRANSCRIPTIONAL ACTIVITY | Nelida Ines Ngguera | ![]() |
![]() |
|||
26-P | THE GENE SIGNATURE IN C/EBPA DYSFUNCTIONAL AML PREDICTS RESPONSIVENESS TO HDAC INHIBITORS | Meritxell Alberich Jorda | ![]() |
![]() |
|||
29-P | THE EFFECT OF ARA-C TREATMENT ON HEMATOPOIETIC STEM CELL EXPANSION AND LEUKEMOGENESIS IN A MOUSE MODEL OF CEBPA MUTANT ACUTE MYELOID LEUKEMIA | monica cimino | ![]() |
![]() |
|||
32-P | C/EBPA REGULATES CXCR4 EXPRESSION IN ACUTE MYELOID LEUKEMIA | Yuan-Yeh Kuo | ![]() |
![]() |
|||
33-P | COMBINED INHIBITION OF C-KIT AND PI3K/MTOR SIGNALLING HAS SYNERGISTIC ACTIVITY IN C-KIT MUTANT AML | Steven Tinsley | ![]() |
![]() |
|||
34-P | THE FUSION GENE NUP98-HOXA9 AS A MODEL FOR LEUKEMOGENESIS: EXPLORING ITS MOLECULAR MECHANISMS AND FUNCTIONAL EFFECTS | ANA RIO-MACHIN | ![]() |
![]() |
|||
35-P | ACID CERAMIDASE PROMOTES ACUTE MYELOID LEUKEMIA SURVIVAL THROUGH MCL-1 UPREGULATION | Su-Fern Tan | ![]() |
![]() |
|||
36-P | ANTILEUKEMIC EFFECT OF PI3K-MTOR INHIBITORS IN ACUTE MYELOID LEUKEMIA- GENE EXPRESSION PROFILES REVEAL CDC25B EXPRESSION AS DETERMINATE OF PHARMACOLOGICAL EFFECT | Hkon Reikvam | ![]() |
![]() |
|||
37-P | L-ASPARAGINASE ALTERS TRANSCRIPTION AND TRANSLATION OF GENES INVOLVED IN METABOLISM IN MYELOID LEUKEMIA | Sung Ah Jun | ![]() |
![]() |
|||
38-P | THE TYROSINE KINASE CSK ASSOCIATES WITH FLT3 AND KIT RECEPTORS AND REGULATES DOWNSTREAM SIGNALING IN ACUTE MYELOID LEUKEMIA | Julhash Kazi | ![]() |
![]() |
|||
39-P | WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS | Hana Hajkova | ![]() |
![]() |
|||
40-P | EXPRESSION OF THE SPLICE VARIANT NPM1-R2 HAS STRONGER PROGNOSTIC VALUE THAN NPM1 MUTATIONAL STATUS IN ACUTE MYELOID LEUKEMIA | Malgorzata Zajac | ![]() |
![]() |
|||
49-P | EX VIVO PHARMACOLOGICAL EVALUATION OF 16 DRUGS IN 60 ACUTE MYELOID LEUKEMIA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY | Belén Liébana | ![]() |
![]() |
|||
50-P | SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTI-CD33 ANTIBODY TREATMENT IN AML GEMTUZUMAB OZOGAMACIN HAS ANTI-LEUKAEMIC EFFICACY | Ching Loke | ![]() |
![]() |
|||
51-P | RISK-ADAPTED TRANSPLANT SELECTION ATTENUATES THE NEGATIVE PROGNOSTIC ROLE OF MINIMAL RESIDUAL DISEASE AND GENETIC HIGH RISK FEATURES | Francesco Buccisano | ![]() |
![]() |
|||
53-P | ELACYTARABINE / IDARUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED CYTARABINE BASED INDUCTION, AND EVALUATION OF THE IMPACT OF THE TRANSPORTER HENT1 ON RESPONSE; RESULTS OF A PHASE II STUDY | Malin Johansen | ![]() |
![]() |
|||
56-P | PATTERNS OF RELAPSE IN 169 PATIENTS TREATED WITH ORAL ARSENIC TRIOXIDE DURING INDUCTION AND/OR MAINTENANCE: A 12-YEAR EXPERIENCE | Harinder Gill | ![]() |
![]() |
|||
57-P | SURVIVAL IMPACT OF COMPLEX AND MONOSOMAL KARYOTYPE AND LOSS OF CHROMOSOMES 5, 7 AND 17 IN OLDER PATIENTS WITH AML. FIRST EVALUATION OF CYTOGENETIC DATA FROM THE POPULATION BASED SWEDISH AML REGISTRY | Vladimir Lazarevic | ![]() |
![]() |
|||
58-P | PATIENTS WITH LATE RELAPSE OF ACUTE MYELOID LEUKEMIA HAVE A HIGH RATE OF DURABLE SECOND COMPLETE REMISSIONS WHEN TREATED WITH CHEMOTHERAPY ONLY | sa Derolf | ![]() |
![]() |
|||
59-P | SURVIVAL IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN GERMANY AND THE UNITED STATES: UNEXPLAINED DIFFERENCES IN SURVIVAL IN YOUNG ADULTS | Dianne Pulte | ![]() |
![]() |
|||
61-P | LOW- DOSE CHEMOTHERAPY AND DIFFERENTIATING AGENTS AS POST- REMISSION MAINTENANCE PROLONGED DISEASE- FREE AND OVERALL SURVIVAL IN A CASE-CONTROL RETROSPECTIVE STUDY ON POOR PROGNOSIS AML/MDS PATIENTS | Crisŕ Elena | ![]() |
![]() |
|||
62-P | A STUDY OF ELACYTARABINE IN RELAPSED OR REFRACTORY AML EVALUATING CARDIAC SAFETY AND PHARMACOKINETIC PROPERTIES | Malin Johansen | ![]() |
![]() |
|||
63-P | MULTI-LINEAGE DYSPLASIA AS ASSESSED BY IMMUNO-PHENOTYPE HAS NO IMPACT ON OUTCOME OF ACUTE MYELOID LEUKEMIA WITH MUTATED NUCLEOPHOSMIN (NPM1) | Francesco Mannelli | ![]() |
![]() |
|||
65-P | MEDIUM-SIZED FLT3 INTERNAL TANDEM DUPLICATIONS CONFER WORSE PROGNOSIS, THAN SHORT AND LONG DUPLICATIONS | Magdalena Koszarska | ![]() |
![]() |
|||
67-P | THERAPY-RELATED MYELOID NEOPLASMS: REPORT OF THE ITALIAN NETWORK ON SECONDARY LEUKEMIAS | LUANA FIANCHI | ![]() |
![]() |
|||
68-P | AZACITIDINE FOR RELAPSE TREATMENT IN MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Benoit Tessoulin | ![]() |
![]() |
|||
69-P | MONITORING MINIMAL RESIDUAL DISEASE IN NPM-1 MUTATED ACUTE MYELOID LEUKEMIA. PRELIMINARY RESULTS AT A SINGLE INSTITUTION | Chiara Pagani | ![]() |
![]() |
|||
70-P | THE PROGNOSTIC IMPACT OF ADDITIONAL KARYOTYPIC ABNORMALITIES IN T(8;21) ACUTE MYELOID LEUKEMIA | Zhentang Lao | ![]() |
![]() |
|||
71-P | BAALC GENE EXPRESSION REDUCTION DURING INDUCTION PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA | vanessa ponziani | ![]() |
![]() |
|||
74-P | SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA | alessandra malato | ![]() |
![]() |
|||
75-P | ACHIEVING BONE MARROW CLL MINIMAL RESIDUAL DISEASE-FREE STATUS WITH FIRST-LINE FCR IS ASSOCIATED WITH IMPROVED PFS AND CAN BE CONSIDERED A PRIMARY TREATMENT OBJECTIVE | PAOLO STRATI | ![]() |
![]() |
|||
76-P | DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC INDEX PATIENTS WITH CLL | Natali Pflug | ![]() |
![]() |
|||
78-P | CHRONIC LYMPHOCYTIC LEUKEMIA CELLS FROM PAIRED LYMPH NODE AND PERIPHERAL BLOOD SHOW A DIFFERENT PATTERN OF COPY NUMBER ABERRATIONS | Silvia Bonina | ![]() |
![]() |
|||
80-P | A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT (TFT) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | JOSE-ANGEL HERNANDEZ | ![]() |
![]() |
|||
81-P | NOTCH1 MUTATED IGHV UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CONSTITUTIVELY OVEREXPRESSED NUCLEOPHOSMIN-1 AND RIBOSOME-ASSOCIATED COMPONENTS | Michele Dal Bo | ![]() |
![]() |
|||
82-P | CLL: DIFFERENT AGES, DIFFERENT ANTIGEN RECEPTOR PROFILES | PANAGIOTIS BALIAKAS | ![]() |
![]() |
|||
83-P | DETECTION OF TP53 DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA BY AN IN VITRO FUNCTIONAL ASSAY BASED ON TP53 ACTIVATION BY THE NON-GENOTOXIC DRUG NUTLIN-3: A PROPOSAL FOR CLINICAL APPLICATION | Federico Pozzo | ![]() |
![]() |
|||
85-P | SEQUENTIAL MRD ANALYSIS IN CLL DEMONSTRATES EXPONENTIAL EXPANSION WITH A PATTERN THAT CANNOT BE PREDICTED FROM PRE-TREATMENT DOUBLING TIME. | Andy Rawstron | ![]() |
![]() |
|||
87-P | UNRAVELING THE HETEROGENEITY OF T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) | Anton W. Langerak | ![]() |
![]() |
|||
88-P | EPIGENETIC INACTIVATION OF MIR-34B/C IN ADDITION TO MIR-34A AND DAPK1 IN CHRONIC LYMPHOCYTIC LEUKEMIA | Luqian WANG | ![]() |
![]() |
|||
91-P | BIALLELIC LOSSES OF 13Q DO NOT CONFER A POORER OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 627 PATIENTS WITH ISOLATED 13Q DELETION. | Anna Puiggros | ![]() |
![]() |
|||
92-P | A HIGH SENSITIVITY METHOD REVEALED A TWOFOLD-INCREASED INCIDENCE OF NOTCH1 MUTATION WITH ADVERSE PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKAEMIA | paolo sportoletti | ![]() |
![]() |
|||
94-P | NOVEL ASSAY FOR THE IDENTIFICATION OF NOTCH1 PEST DOMAIN MUTATIONS USING FRAGMENT ANALYSIS AND ALLELE SPECIFIC PCR | Paulo Campregher | ![]() |
![]() |
|||
95-P | LONG-LASTING RESPONSES TO LENALIDOMIDE AS INITIAL THERAPY OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | PAOLO STRATI | ![]() |
![]() |
|||
96-P | LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP | Luká Smolej | ![]() |
![]() |
|||
97-P | PLATINUM AND HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTERS SYNDROME: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY | Eric DUROT | ![]() |
![]() |
|||
99-P | TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | Stephen Mulligan | ![]() |
![]() |
|||
101-P | PRELIMINARY RESULTS FROM A SURVEY OF REAL-LIFE FIRST LINE THERAPY OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE UK | Tony Todd | ![]() |
![]() |
|||
103-P | INCREASED EXPRESSION OF THE EZH2 METHYLTRANSFERASE AND EVIDENCE OF FUNCTIONALITY IN CLL SUBGOUPS WITH AGGRESSIVE CLINICOBIOLOGICAL PROFILES | Nikos Papakonstantinou | ![]() |
![]() |
|||
104-P | OUTCOMES OF PATIENTS WITH FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) A POPULATION-BASED STUDY FROM A WELL-DEFINED GEOGRAPHIC REGION | Sandra Eketorp Sylvan | ![]() |
![]() |
|||
105-P | PROLONGED CYTOPENIA RELATED TO FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA | PAOLO STRATI | ![]() |
![]() |
|||
106-P | FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P | PAOLO STRATI | ![]() |
![]() |
|||
108-P | UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA. | Miguel Piris-Villaespesa | ![]() |
![]() |
|||
110-P | THE PROGNOSTIC VALUE OF THE NUMBER OF CELLS WITH A DELETION OF 13Q14 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | Ekaterina Zotina | ![]() |
![]() |
|||
113-P | IMATINIB OR DASATINIB TREATMENT OF CHRONIC MYELOID LEUKEMIA REDUCES CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AND INCREASES THEIR CD40 EXPRESSION | Stina Sderlund | ![]() |
![]() |
|||
114-P | THE AXIS SHP-1/SHP-2 MODULATES VEGFR2 SIGNALING IN CML CELL LINES: VEGFR2 DEREGULATION MAY BE IMPLICATED IN IMATINIB (IMA) RESISTANCE | Nicola Esposito | ![]() |
![]() |
|||
115-P | SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS (TKIS) TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW (BM) STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA (CML) | Concetta Quintarelli | ![]() |
![]() |
|||
116-P | CHRONIC MYELOID LEUKEMIA WITH VARIANT T(9;22) REVEALS A DIFFERENT SIGNATURE FROM CASES WITH CLASSIC TRANSLOCATION. | Francesco Albano | ![]() |
![]() |
|||
118-P | REDUCED EXPRESSION OF CHIBBY IS A COMPONENT OF BETA-CATENIN ACTIVATION IN CHRONIC MYELOID LEUKEMIA STEM CELLS | Elisa Leo | ![]() |
![]() |
|||
119-P | DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA | Tomasz Stoklosa | ![]() |
![]() |
|||
120-P | MYELOID-DERIVED SUPPRESSOR CELLS ARE INCREASED IN CHRONIC MYELOID LEUKEMIA AND EXERT IMMUNE SUPPRESSIVE ACTIVITY | Cesarina Giallongo | ![]() |
![]() |
|||
121-P | CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS | Sung-Eun Lee | ![]() |
![]() |
|||
122-P | DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED | Caterina De Benedittis | ![]() |
![]() |
|||
124-P | A NEW NON CANONICAL ROLE OF IKB ALPHA IN CHRONIC MYELOID LEUKEMIA PATHOGENESIS | Cristina Panuzzo | ![]() |
![]() |
|||
125-P | L-AMINO ACID OXIDASE ISOLATED FROM BOTHROPS PIRAJAI INDUCES APOPTOSIS IN BCR-ABL POSITIVE CELLS AND POTENTIATES IMATINIB MESYLATE EFFECT | sandra burin | ![]() |
![]() |
|||
126-P | IL-2, IL-12 AND IL-15 PREVENT REACTIVE OXYGEN SPECIES ACCUMULATION ON NATURAL KILLER CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS FOLLOWING INTERFERON-ALPHA, IMATINIB AND DASATINIB THERAPY | Paulo Rodrigues Santos | ![]() |
![]() |
|||
127-P | EFFECT OF NILOTINIB ON THE FUNCTION OF CAROTID ARTERY ENDOTHELIAL CELLS | mr Gkmen Sevindik | ![]() |
![]() |
|||
128-P | STANDARDIZATION OF MRD DETECTION IN CML BY USE OF A PEER GROUP CONVERSION FACTOR | Els Dumoulin | ![]() |
![]() |
|||
129-P | BIOLOGICAL CHARACTERISTICS AND DYNAMICS OF BCR-ABL1 MULTIPLE MUTATIONS IN TYROSINE KINASE INHIBITOR RESISTANT CML | Soohyun Kim | ![]() |
![]() |
|||
131-P | 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML) | CLAIRE LUCAS | ![]() |
![]() |
|||
132-P | IMPACT OF DRUG TRANSPORTER ABCG2 HAPLOTYPES IN MOLECULAR RESPONSE OF CML PATIENTS IS MODULATED BY IMATINIB DAILY DOSE | delord marc | ![]() |
![]() |
|||
135-P | FIFTEEN-MONTH UPDATE OF A PHASE II TRIAL OF THE COMBINATION OF PEGYLATED INTERFERON ALPHA2ANILOTINIB AS FIRST LINE THERAPY FOR NEWLY DIAGNOSED CHRONIC PHASE CML PATIENTS | Franck Nicolini | ![]() |
![]() |
|||
142-P | HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: RESULTS OF A GERMAN CROSS-SECTIONAL STUDY IN PATIENTS PREVIOUSLY REGISTERED IN PROSPECTIVE, CONTROLLED CLINICAL TRIALS | Susanne Sauele | ![]() |
![]() |
|||
144-P | DISCONTINUATION OF BCR-ABL1 TYROSINE KINASE INHIBITOR IN CML PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR: INCLUDING UPDATED DATA FROM KIDS STUDY | Yun jeong Oh | ![]() |
![]() |
|||
146-P | EFFICACY OF NILOTINIB VERSUS HIGH-DOSE IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSES TO STANDARD-DOSE IMATINIB: MULTICENTER RE-NICE STUDY | Soo Young Choi | ![]() |
![]() |
|||
147-P | OCT1 GENETIC VARIANTS ARE ASSOCIATED WITH LONG TERM OUTCOMES IN IMATINIB TREATED CML PATIENTS | Maya Koren-Michowitz | ![]() |
![]() |
|||
150-P | MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA | Zdenek Racil | ![]() |
![]() |
|||
152-P | FLOW CYTOMETRY EARLY DETECTION OF CD4CD26-CD38 LYMPHOCYTES SUBSET IN LYMPH NODES OF HODGKIN LYMPHOMA | Giuseppe Tagariello | ![]() |
![]() |
|||
153-P | FIRST-LINE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA FINAL RESULTS OF A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS | Michaela Rancea | ![]() |
![]() |
|||
155-P | A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS | Paul Greaves | ![]() |
![]() |
|||
158-P | ESHAP AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS LYMPHOMA | Jorge Labrador | ![]() |
![]() |
|||
160-P | THE LYMPHOCYTIC HISTOPATHOLOGIC SUBTYPES OF HODGKIN LYMPHOMA (HL): CLINICAL PRESENTATION AND LONG-TERM OUTCOME IN A CASE SERIES OF 61 PATIENTS | Theodoros Vassilakopoulos | ![]() |
![]() |
|||
161-P | LONG TERM RESULTS OF MONOCENTRIC PROSPECTIVE STUDY OF VEBEP PLUS RADIOTHERAPY REGIMEN IN NEWLY DIAGNOSED EARLY-UNFAVORABLE STAGE HODGKIN LYMPHOMA | SIMONA PAGLIUCA | ![]() |
![]() |
|||
162-P | DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PRIMARY REFRACTORY HODGKINS LYMPHOMA TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION | Marianna David | ![]() |
![]() |
|||
163-P | HETEROGENEOUS MANAGEMENT OF ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA AND INCONSTANT CONFORMITY OF MEDICAL PRACTICE TO CLINICAL GUIDELINES: EXHAUSTIVE COHORT FROM RHNE-ALPES REGION | Arthur Dony | ![]() |
![]() |
|||
166-P | RECURRENT SETBP1 MUTATIONS IN ATYPICAL CHRONIC MYELOID LEUKEMIA | SARA REDAELLI | ![]() |
![]() |
|||
168-P | ABERRANT SPLICING DURING ERYTHROID DIFFERENTIATION IN SF3B1 MUTATED SIDEROBLASTIC ANEMIA | Simona Conte | ![]() |
![]() |
|||
169-P | RESISTANCE TO APOPTOSIS IN HIGH-RISK MYELODYSPLASTIC SYNDROME CAN BE OVERCOME BY PRO-APOPTOTIC DRUG TREATMENT USING ABT-737 | Stefanie Jilg | ![]() |
![]() |
|||
173-P | A PAIR MONOZYGOTIC TWINS WITH CONCORDANT JUVENILE MYELOMONOCYTIC LEUKEMIA: INSIGHT IN THE COURSE OF THE DISEASE | Silvia Bresolin | ![]() |
![]() |
|||
174-P | FAMILIAL, NON-ZINC FINGER REGION, GATA2 MUTATED MYELODYSPLASTIC SYNDROME; ASSOCIATED WITH SHORTENED TELOMERE LENGTHS, VIRAL WARTS, PROFOUND MONOCYTE/B/NK CELL DEFICIENCY | Mrinal Patnaik | ![]() |
![]() |
|||
175-P | EVALUATION OF PRO-SURVIVAL PATHWAYS, INCLUDED AUTOPHAGY, IN HIGH-RISK MDS BONE MARROW AFTER TREATMENT WITH 5-AZACITIDINE TO RESTORE NORMAL HEMATOPOIESIS | ALESSANDRA ROMANO | ![]() |
![]() |
|||
177-P | FLOW CYTOMETRIC CLASSIFICATION OF 350 TYPE III PNH CLONES IN ITALY: A MULTI-CETRIC STUDY | ELISA CANNIZZO | ![]() |
![]() |
|||
178-P | CYTOGENETIC CHARACTERIZATION OF CD34 HEMATOPOIETIC PROGENITOR CELLS AND MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME (MDS) | Maria Pimenova | ![]() |
![]() |
|||
179-P | POLYMORPHISMS IN GENES INVOLVED IN DNA REPAIR AND FOLATE PATHWAY SIGNIFICANTLY IMPACT ON SURVIVAL IN LOW-RISK, UNTREATED MYELODYSPLASIA. | Giuseppe Visani | ![]() |
![]() |
|||
183-P | EVALUATION OF A HIGH THROUGHPUT MUTATION-SCREENING STRATEGY IN MYELODYSPLASTIC SYNDROME PATIENTS AND ACUTE MYELOID LEUKEMIA USING TARGETED-GENE ENRICHMENT TECHNOLOGY | Mohsen Karimi Arzenani | ![]() |
![]() |
|||
184-P | Impact of 5q Breakpoints on Clinical Outcomes in Patients With IPSS Low/Int-1-Risk Myelodysplastic Syndromes (MDS) and Isolated del(5q) Treated With Lenalidomide in the MDS-004 Study | Gudrun Ghring | ![]() |
![]() |
|||
185-P | PROGNOSTIC IMPACT OF DER(1;7) IN MDS IS DIFFERENT FROM DEL(7Q) | Julie Schanz | ![]() |
![]() |
|||
186-P | CLINICAL SIGNIFICANCE OF ASXL1 MUTATION IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROME AND ITS STABILITY DURING DISEASE PROGRESSION | Tsung Chih Chen | ![]() |
![]() |
|||
188-P | HIGH DOSES OF ELTROMBOPAG ARE WELL-TOLERATED IN CONJUNCTION WITH AZACITIDINE AND THE COMBINATION DEMONSTRATES ENCOURAGING ACTIVITY IN PATIENTS WITH MDS AND AML. | Michael Dickinson | ![]() |
![]() |
|||
195-P | IMPROVED PREDICTIVE PROGNOSTIC POWER OF REVISED-IPSS (IPSS-R) IN A SERIES OF 301 PATIENTS WITH MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER. | Montserrat Arnan Sangerman | ![]() |
![]() |
|||
197-P | HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE | Ota Fuchs | ![]() |
![]() |
|||
199-P | MORTALITY BURDEN OF TRANSFUSION DEPENDENCY AND IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. | Montserrat Arnan Sangerman | ![]() |
![]() |
|||
200-P | NOVEL 3Q26 DELETION BONE MARROW FAILURE SYNDROME IN A NEWBORN RESULTING IN DOMINANT NEGATIVE INTERFERENCE OF HEMATOPOIESIS BY TRUNCATED EVI1/MECOM | Lars van der Veken | ![]() |
![]() |
|||
202-P | EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS)IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES. | Hege Garelius | ![]() |
![]() |
|||
204-P | ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN-FLUFENAMIDE | Dharminder Chauhan | ![]() |
![]() |
|||
205-P | METABOLOMIC PROFILING IDENTIFIES MECHANISMS REGULATING HYPOXIA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA. | Patricia Maiso | ![]() |
![]() |
|||
206-P | GENOMIC CHARACTERIZATION OF THE PUTATIVE MULTIPLE MYELOMA STEM CELLS CLONE REVEALS COPY NUMBER ALTERATIONS (CNAS) POSSIBLY CORRELATED WITH THE ORIGIN OF DISEASE | Marina Martello | ![]() |
![]() |
|||
207-P | MULTIDIMENSIONAL FLOW CYTOMETRY FOR SENSITIVE EVALUATION OF PATIENTS WITH IGM MGUS OR WALDENSTROMS MACROGLOBULINEMIA AND DIFFERENTIAL DIAGNOSIS WITH OTHER LYMPHOMAS | Bruno Paiva | ![]() |
![]() |
|||
208-P | IDENTIFICATION OF SERUM MICRORNA PROFILE IN MULTIPLE MYELOMA ASSOCIATED WITH COMPLETE REMISSION AND PROGRESSION AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION | Carlos Fernández de Larrea | ![]() |
![]() |
|||
209-P | IMPROVED ACCURACY OF DISCRIMINATION BETWEEN IGM MULTIPLE MYELOMA (MM) AND WALDENSTROEMS MACROGLOBULINAEMIA (WM) BY TESTING FOR MYD88 L265P MUTATIONS | Wolfgang Willenbacher | ![]() |
![]() |
|||
210-P | ABT-199 IS HIGHLY EFFECTIVE AGAINST MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA HARBORING T(11;14) TRANSLOCATION | Cyrille Touzeau | ![]() |
![]() |
|||
214-P | MULTIDIMENSIONAL FLOW CYTOMETRY IMMUNOPHENOTYPIC QUANTIFICATION AND CHARACTERIZATION OF IN VIVO MESENCHYMAL STEM CELLS IN MGUS AND MULTIPLE MYELOMA | Rui Leite | ![]() |
![]() |
|||
216-P | AN EGFP IMAGING BASED IN VIVO MODEL FOR STUDYING THE BIOLOGY AND TREATMENT OF MULTIPLE MYELOMA | lisha ai | ![]() |
![]() |
|||
217-P | IDENTIFICATION OF POTENTIAL DRUG TARGETS WITHIN THE UBIQUITIN PROTEASOME SYSTEM IN MULTIPLE MYELOMA | Lisa Crawford | ![]() |
![]() |
|||
218-P | MULTIPARAMETER FLOW CYTOMETRY DETECTION OF CLONAL PLASMA CELLS IN THE BONE MARROW OF PATIENTS WITH SOLITARY PLASMACYTOMA DETERMINES THE RISK OF PROGRESSION TO ACTIVE MYELOMA | Bruno Paiva | ![]() |
![]() |
|||
219-P | CAN IMMUNOPHENOTYPIC CR BE ALSO ACHIEVED IN RELAPSED MULTIPLE MYELOMA PATIENTS? | Bruno Paiva | ![]() |
![]() |
|||
220-P | MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELL NUMBERS | Jacqueline Noll | ![]() |
![]() |
|||
221-P | EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL | Francesca Gay | ![]() |
![]() |
|||
223-P | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE VERSUS THALIDOMIDE-DEXAMETHASONE PLUS AUTOTRANSPLANTATION FOR MULTIPLE MYELOMA: UPDATED FOLLOW-UP AND OUTCOMES AFTER RELAPSE IN THE PHASE 3 GIMEMA-MMY-3006 TRIAL | paola tacchetti | ![]() |
![]() |
|||
226-P | MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) | Paul Richardson | ![]() |
![]() |
|||
227-P | TANDEM AUTOLOGOUS/ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS IN FIRST LINE HIGH RISK MULTIPLE MYELOMA PATIENTS: EVOLVING STRATEGIES WITH THE IMMUNOMODULATING DRUGS | Mauricette Michallet | ![]() |
![]() |
|||
231-P | BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009-01 TRIAL): PREDICTIVE FACTORS OF DEFAVOURABLE OUTCOME | Philippe Rodon | ![]() |
![]() |
|||
235-P | A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA | Hiroyuki Takamatsu | ![]() |
![]() |
|||
241-P | IMPACT OF HISTORY OF AUTOIMMUNE DISEASE ON SURVIVAL IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | Ebba Lindqvist | ![]() |
![]() |
|||
242-P | LOW RATE OF SECONDARY PRIMARY MALIGNANCIES (SPMS) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH LENALIDOMIDE: FIRST RESULTS FROM THE MRC MM XI TRIAL | Annamaria Brioli | ![]() |
![]() |
|||
243-P | THERAPY FOLLOWING RELAPSE ON MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) FOLLOWED BY LEN MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFICACY AND SAFETY OF SECOND LINE LEN IN MM-015 | Meletios Dimopoulos | ![]() |
![]() |
|||
244-P | ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | Katja Weisel | ![]() |
![]() |
|||
245-P | SALVAGE TREATMENT WITH POMALIDOMIDE-CYCLOPHOSPHAMIDE-PREDNISONE PRODUCES SIMILAR OUTCOMES AS COMPARED TO PRIOR THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | Alessandra Larocca | ![]() |
![]() |
|||
248-P | A MOUSE MODEL FOR HUMAN MYELOFIBROSIS | IOANNA TRIVIAI | ![]() |
![]() |
|||
249-P | DEREGULATED MIRNAS IN JAK2V617F-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS TARGET SOCS FAMILY MEMBERS | Beatriz Bellosillo | ![]() |
![]() |
|||
250-P | A DIFFERENTIAL CENTROSOME LOCALIZZATION OF WILD TYPE (WT) AND JAK2V617F PROTEIN IN HUMAN LEUKEMIA CELL LINES | Biagio De Angelis | ![]() |
![]() |
|||
251-P | EVALUATION OF THROMBIN GENERATION POTENTIAL IN POLYCYTHEMIA VERA PATIENTS ENROLLED IN THE CYTO-PV ITALIAN CLINICAL TRIAL | Marina Marchetti | ![]() |
![]() |
|||
253-P | A TRANSLOCATION T(3 ;13)(Q13 ;Q12) FUSES FLT3 TO A NOVEL PARTNER GENE, GOLGB1, IN A MYELOID/LYMPHOID NEOPLASM WITH EOSINOPHILIA. | Estelle TROADEC | ![]() |
![]() |
|||
255-P | INCREASED PREVALENCE OF AUTOIMMUNE PHENOMENA IN MYELOFIBROSIS: RELATIONSHIP WITH CLINICAL AND MORPHOLOGICAL CHARACTERISTICS, AND WITH IMMUNOREGULATORY CYTOKINE PATTERNS | Francesca Guidotti | ![]() |
![]() |
|||
257-P | ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO. | Novella Pugliese | ![]() |
![]() |
|||
258-P | SETBP1 OVEREXPRESSION IN CLASSICAL BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS | Francesco Albano | ![]() |
![]() |
|||
259-P | CUSTOM AMPLICON CAPTURE AND BENCH-TOP HIGH THROUGHPUT SEQUENCING TO SCREEN FOR MUTATIONS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASMS | Gareth Gerrard | ![]() |
![]() |
|||
260-P | QUANTITATIVE RT-PCR FOR PDGFR IS USEFUL FOR DIAGNOSIS AND MOLECULAR MONITORING OF PATIENTS WITH PDGFR REARRANGEMENTS TREATED WITH TYROSINE-KINASE INHIBITORS | Eric Lippert | ![]() |
![]() |
|||
261-P | CHARACTERIZATION OF PLATELET HYPERCOAGULABILITY IN HIGH-HEMATOCRIT POLYCYTHEMIA VERA PATIENTS | Marina Marchetti | ![]() |
![]() |
|||
262-P | CHARACTERIZATION OF MUTATIONS IN ASXL1, SRSF2, CBL AND JAK2 GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA | Laura Palomo | ![]() |
![]() |
|||
263-P | ADDITIONAL MUTATIONS TARGETING GENES UNRELATED TO RAS PATHWAY ARE FOUND IN SPORADIC JMML BUT NOT IN SYNDROMIC JMML | Aurélie Caye | ![]() |
![]() |
|||
264-P | DETECTION OF LEUKEMIA-ASSOCIATED MUTATIONS IN HEMATOLOGICALLY NORMAL ELDERLY INDIVIDUALS | Joannah Score | ![]() |
![]() |
|||
265-P | THE IDENTIFICATION OF A PSTAT5 GENE SIGNATURE AND ITS MODULATION IN RUXOLITINIB PHARMACODYNAMIC RESPONSE IN HEMATOLOGIC MALIGNANCY | Jessica Litvan | ![]() |
![]() |
|||
266-P | DO MYELOPROLIFERATIVE NEOPLASMS (MPNS) HAVE STAGES? ANALYSIS OF RELATIONSHIP OF DISEASE DURATION, PROGNOSTIC SCORES, AND SYMPTOMATIC BURDEN OF 1467 MPN PATIENTS | Holly Geyer | ![]() |
![]() |
|||
268-P | MUTATIONS IN THE RNA SPLICING MACHINERY GENES IN MYELOFIBROTIC TRANSFORMATION OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA | Beatriz Bellosillo | ![]() |
![]() |
|||
269-P | MULTIVARIATE ANALYSIS OF THE ASSOCIATION OF CYTOKINE LEVELS AND REDUCTIONS IN SPLEEN SIZE IN COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB TO BEST AVAILABLE THERAPY (BAT) | Jessica Litvan | ![]() |
![]() |
|||
270-P | SPLICEOSOME COMPONENT MUTATIONS AND CYTOGENETIC CORRELATES IN WORLD HEALTH ORGANIZATION (WHO)-DEFINED CHRONIC MYELOMONOCYTIC LEUKEMIA | Sameer Parikh | ![]() |
![]() |
|||
271-P | ACQUIRED COPY-NEUTRAL LOSS OF HETEROZIGOSITY OF CHROMOSOME 1P AS A MOLECULAR EVENT ASSOCIATED WITH MARROW FIBROSIS IN MPL MUTATED MYELOPROLIFERATIVE NEOPLASMS | elisa rumi | ![]() |
![]() |
|||
273-P | MYELOPROLIFERATIVE NEOPLASM QUALITY OF LIFE (MPN-QOL) STUDY GROUP: DUAL SERIAL ASSESSMENT STUDIES FOR IMPACT OF STANDARD THERAPEUTIC APPROACHES IN MPN POPULATIONS (MEASURE AND SYMPTOMS TRIALS) | Holly Geyer | ![]() |
![]() |
|||
274-P | LONG-TERM EFFICACY AND SAFETY OF CLADRIBINE (2-CDA) IN ADULT PATIENTS WITH MAST CELL DISEASE : A FRENCH MULTICENTER STUDY OF 68 PATIENTS | stephane BARETE SB | ![]() |
![]() |
|||
275-P | CIRCULATING YKL-40 IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) TREATED WITH THE NOVEL HISTONE DEACETYLASE INHIBITOR VORINOSTAT | Christen Andersen | ![]() |
![]() |
|||
276-P | IMPACT OF HEMATOCRIT ON SYMPTOM BURDEN AMONG POLYCYTHEMIA VERA PATIENTS | Robyn Emanuel | ![]() |
![]() |
|||
277-P | WHITE BLOOD CELLS COUNT INFLUENCE THE PROGNOSIS OF POLYCYTHEMIA VERA PATIENTS: A SUB-ANALYSIS OF THE CYTO-PV STUDY. | RICCARDO CAVAZZINA | ![]() |
![]() |
|||
278-P | Safety Overview of Phase 1-2 Studies of Pacritinib, a Non-Myelosuppressive JAK2/FLT3 inhibitor, in Patients with Hematological Malignancies | Kristin MacIntosh | ![]() |
![]() |
|||
279-P | A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF) | Christen Andersen | ![]() |
![]() |
|||
280-P | CLINICAL FEATURES OF ESSENTIAL THROMBOCYTHEMIA WITH SPLEEN ENLARGEMENT: THE EXPERIENCE OF LAZIAL GROUP FOR THE STUDY OF SMPC, PH-. | Alessandro Andriani | ![]() |
![]() |
|||
284-P | DETECTION OF PERIPHERAL BLOOD MONOCLONAL T LYMPHOCYTOSIS AND RISK OF T LYMPHOPROLIFERATIVE DISEASE DEVELOPMENT | Giuseppe Tagariello | ![]() |
![]() |
|||
286-P | VITAMIN D3 AND LENALIDOMIDE SYNERGIZE TO INDUCE APOPTOSIS IN MANTLE CELL LYMPHOMA VIA DEMETHYLATION OF BIK | Carole Brosseau | ![]() |
![]() |
|||
288-P | THE HOST GENETIC BACKGROUND MODULATES TREATMENT ACTIVITY AND TOXICITY IN FOLLICULAR LYMPHOMA: FIL-FOLL05 TRIAL | Giuseppe Palumbo | ![]() |
![]() |
|||
292-P | MYD88 L265P MUTATION IN WALDENSTROM MACROGLOBULINEMIA : INCIDENCE AND FUNCTIONAL STUDY | Stephanie Poulain | ![]() |
![]() |
|||
294-P | B-CELL REPERTOIRE ANALYSIS OF INDOLENT MCL WITH SPLENIC PRESENTATION : A DISTINCT ONTOGENY FROM CLASSICAL MCL? | clémentine sarkozy | ![]() |
![]() |
|||
296-P | INFLUENCE OF THE B-CELL RECEPTOR (BCR) SIGNALING PATHWAYS ON CD20 LEVELS IN TUMOR CELLS AND ANTITUMOR ACTIVITY OF ANTI-CD20 MONOCLONAL ANTIBODIES | Magdalena Winiarska | ![]() |
![]() |
|||
297-P | GENETIC VARIATION IN INTERFERON REGULATORY FACTOR 4 AND INTERLEUKIN 10 GENES, AND THE RISK FOR DIFFUSE LARGE B-CELL LYMPHOMA | In-Suk Kim | ![]() |
![]() |
|||
298-P | PROGNOSTIC IMPACT OF EZH2 EXPRESSION, H3K27 TRIMETHYLATION AND DNA METHYLATION IN DIFFUSE LARGE B CELL LYMPHOMA | Shih-Chiang Lin | ![]() |
![]() |
|||
299-P | BMI1 EXERTS ITS ONCOGENIC EFFECTS VIA ENHANCEMENT OF ANTI-APOPTOTIC POTENTIAL IN MANTLE CELL LYMPHOMA | kazuaki teshima | ![]() |
![]() |
|||
300-P | THE ROLE OF CXCCHEMOKINE IL-8, IL-6 AND CXCR2 RECEPTOR IN LYMPHOPLASMACYTIC LYMPHOMA: CORRELATIONS WITH MICROVASCULAR CHARACTERISTICS AND CLINICAL FEATURES | Georgia Levidou | ![]() |
![]() |
|||
301-P | HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA | Rita Coutinho | ![]() |
![]() |
|||
302-P | Upfront allogenic stem cell transplantation in patients with advanced T-cell lymphomas : an intention-to-treat analysis from a single institution | Marion Loirat | ![]() |
![]() |
|||
304-P | R-CHOP21 VS R-CHOP14 IN 1024 DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS FROM A MULTICENTRE RETROSPECTIVE STUDY OF FONDAZIONE ITALIANA LINFOMI (FIL) | Luigi Rigacci | ![]() |
![]() |
|||
305-P | SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES | Marybeth McKenzie | ![]() |
![]() |
|||
307-P | INFERIOR OUTCOME OF ELDERLY DLBCL PTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB: RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP DSHNHL | Jrg Thomas Bittenbring | ![]() |
![]() |
|||
310-P | PIXANTRONE MONOTHERAPY IN HISTOLOGICALLY CONFIRMED, RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: POST HOC ANALYSIS FROM A PHASE III TRIAL | Arthur Smyth Medina | ![]() |
![]() |
|||
311-P | SOX11 CAN BE USED AS A LONGITUDINAL MINIMAL RESIDUAL DISEASE MARKER FOR MANTLE CELL LYMPHOMA | Anita Simonsen | ![]() |
![]() |
|||
312-P | CONTRIBUTION OF CEREBROSPINAL FLUID SCD19 LEVELS TO THE DETECTION OF CNS LYMPHOMA: IMPACT ON DISEASE OUTCOME | Lourdes Martin Martin | ![]() |
![]() |
|||
313-P | RITUXIMAB-PECC FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION IN RELAPSED OR REFRACTORY DLBCL PATIENTS WHO ARE NOT ELIGIBLE FOR OR AFTER ASCT: PRELIMINARY RESULTS FROM A PHASE II HOVON STUDY | Pieternella Lugtenburg | ![]() |
![]() |
|||
316-P | EFFICACY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A MULTICENTRIC STUDY. | Federica Loscocco | ![]() |
![]() |
|||
317-P | THE ROLE OF PET/CT AFTER RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): RESPONSE ASSESSMENT, PROGNOSTIC SIGNIFICANCE AND IMPLICATIONS FOR SUBSEQUENT RADIOTHERAPY (RT) | Theodoros Vassilakopoulos | ![]() |
![]() |
|||
319-P | THE LYMPHOCYTES TO MONOCYTES RATIO IDENTIFIES A PATIENT SUBGROUP AMONG HIGH RISK DLBCL THAT MAY BENEFIT FROM UPFRONT INTENSIVE TREATMENT WITH AUTOGRAFT | Anna Maria Barbui | ![]() |
![]() |
|||
321-P | NON-INTERVENTIONAL STUDY BE-1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON-HODGKIN LYMPHOMA (NHL) IN TREATMENT ROUTINE | Tessa Schliephacke | ![]() |
![]() |
|||
322-P | THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA | Maria Chiara Tisi | ![]() |
![]() |
|||
324-P | LYMPHOMAS WITH MYC-TRANSLOCATION OTHER THAN BURKITTS: BAD PROGNOSIS DESPITE SPECIFIC IMMUNOCHEMOTHERAPY FOR BURKITTS LYMPHOMA | José Tomás Navarro | ![]() |
![]() |
|||
326-P | THE POTENTIAL OF CD127 AS A PROGNOSTIC AND RESIDUAL DISEASE MARKER IN CHRONIC ADULT T CELL LEUKEMIA/LYMPHOMA. | Huseini Kagdi | ![]() |
![]() |
|||
327-P | EVALUATION OF THE PROGNOSTIC SIGNIFICANCE OF THE BODY MASS INDEX (BMI) IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) RECEIVING RITUXIMAB-CHOP (R-CHOP) OR SIMILAR IMMUNOCHEMOTHERAPY | Theodoros Vassilakopoulos | ![]() |
![]() |
|||
328-P | AIDS-RELATED LYMPHOMAS (ARL), OUTCOME AND PROGNOSTIC FACTORS | TERESA GARRIDO | ![]() |
![]() |
|||
330-P | THE USE OF SYSTEMIC THERAPY DOES NOT IMPROVE THE RESULTS OF LOCOREGIONAL TREATMENT IN LIMITED STAGE (I-II) FOLLICULAR LYMPHOMA: STUDY OF 112 PATIENTS. | Juan-Manuel Sancho | ![]() |
![]() |
|||
332-P | CLINICAL AND MOLECULAR SIGNIFICANCE OF TUMOR NECROSIS IN NEWLY DIAGNOSED PATIENTS WITH HODGKINS LYMHOMA AND DIFFUSE LARGE B CELL LYMPHOMA | Ihab Abd el rahman | ![]() |
![]() |
|||
335-P | CLINICAL RELEVANCE OF INTERNATIONAL PROGNOSTIC INDEX AS A PREDICTOR FOR VENOUS THROMBOEMBOLISM IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY | Sung Hee Lim | ![]() |
![]() |
|||
338-P | LOWER INCIDENCE OF EBV-POSITIVITY IN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA: POSSIBLE NEW SUBGROUP OF ELDERLY B-CELL LYMPHOMA | Tatsuki Tomikawa | ![]() |
![]() |
|||
341-P | UTILITY OF F-18 FDG PET/CT FOR THE DIAGNOSIS AND THERAPEUTIC MANAGEMENT FOR EXTRANODAL NATURAL KILLER (NK)/T CELL LYMPHOMA, NASAL TYPE | Bing Xu | ![]() |
![]() |
|||
344-P | LONG TERM SURVEY OF 180 PATIENTS TRANSPLANTED AFTER RIC REGIMEN USING THREE DOSES OF ATG: A BELGIAN HEMATOLOGY SOCIETY (BHS) NATIONAL PROSPECTIVE TRIAL | Dominique Bron | ![]() |
![]() |
|||
345-P | SPECTRUM OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
346-P | ENTERAL VERSUS PARENTERAL NUTRITIONAL SUPPORT POST ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION RESULTS OF A RANDOMIZED CONTROLLED TRIAL | Sarah Andersen | ![]() |
![]() |
|||
347-P | COMBINED CMV REPLICATION AND CHRONIC GVHD GENERATE A SIGNIFICANT SYNERGY OF ANTI-LEUKEMIC EFFECT AFTER ALLOGENEIC HSCT IN ACUTE MYELOID LEUKEMIA | Ji Eun Jang | ![]() |
![]() |
|||
348-P | HUMAN HERPESVIRUS-6 REACTIVATION AND HHV-6 ENCEPHALITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER, PROSPECTIVE STUDY. | Masao Ogata | ![]() |
![]() |
|||
349-P | CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN AML PATIENTS WITH CNS DISEASE UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION- RISK FACTORS AND PROGNOSIS | Mrinal Patnaik | ![]() |
![]() |
|||
350-P | COMPARISON OF MESENCHYMAL STEM CELLS AND MESENCHYMAL STEM CELLS COMBINED WITH CORD BLOOD FOR TREATMENT OF ENGRAFT FAILURE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE PI | Qifa Liu | ![]() |
![]() |
|||
351-P | ABCG2 OVEREXPRESSION NEGATIVELY AFFECT OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA PATIENTS | Mario Tiribelli | ![]() |
![]() |
|||
353-P | A LEBANESE-ITALIAN COLLABORATIVE INITIATIVE ON BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ?-THALASSEMIA MAJOR | Hussein Abbas | ![]() |
![]() |
|||
356-P | CIDOFOVIR AS SECOND LINE THERAPY IN CMV REACTIVATION: CLINICAL AND BIOLOGICAL CORRELATES. | Francesca Farina | ![]() |
![]() |
|||
357-P | IS IMATINIB MAINTENANCE REQUIRED FOR PATIENTS WITH RELAPSE CHRONIC MYELOID LEUKEMIA POST-TRANSPLANTATION OBTAINING CMR? A PILOT RETROSPECTIVE INVESTIGATION | Qifa Liu | ![]() |
![]() |
|||
359-P | UNRELATED CORD BLOOD TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA | Changcheng Zheng | ![]() |
![]() |
|||
360-P | LENOGRASTIM FROM DAY 7 AND PEGFILGRASTIM ARE EQUALLY EFFECTIVE IN REDUCING TIME TO NEUTROPHIL ENGRAFTMENT, ANTIBIOTIC USE AND INPATIENT STAY IN PATIENTS WITH MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT | Benjamin Bailiff | ![]() |
![]() |
|||
361-P | TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE. | CARMEN ALBO | ![]() |
![]() |
|||
364-P | DONOR AND RECIPIENT STR ANALYSIS BEFORE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: POSSIBLE CORRELATION WITH POST-TRANSPLANT OUTCOME | Sabrina Giammarco | ![]() |
![]() |
|||
365-P | COMPARISON BETWEEN LONG-TERM AND SHORT-TERM ADMINISTRATION OF ITRACONAZOLE FOR PRIMARY ANTIFUNGAL PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER, RANDOMIZED TRIAL | Qifa Liu | ![]() |
![]() |
|||
366-P | BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCE LONG-LASTING COMPLETE REMISSIONS IN A HIGH PROPORTION OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: 32 MONTHS FOLLOW-UP UPDATE. | Alessandro Isidori | ![]() |
![]() |
|||
367-P | A CONDITIONING PLATFORM WITH FLUDARABINE, BUSULFAN AND ATG CONDUCTS TO IDENTICAL PROMISING RESULTS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM BOTH MATCHED AND MISMATCHED UNRELATED DONOR | devillier raynier | ![]() |
![]() |
|||
368-P | MOLECULAR MONITORING AND STEPWISE PREEMPTIVE THERAPY FOR EPSTEIN-BARR VIRUS VIREMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
371-P | REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULTS USING FLUDARABINE, BCNU, MELPHALAN, AND ANTITHYMOCYTE GLOBULIN (FBM-A): OUTCOMES DEPEND ON DISEASE RISK INDEX | Jose Leis | ![]() |
![]() |
|||
373-P | PREDICTION OF MOBILIZATION FAILURE FOR PRE-EMPTIVE PLERIXAFOR ADMINISTRATION: THE PAMPLONA PROTOCOL | AMAYA ZABALZA | ![]() |
![]() |
|||
374-P | DOES ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOME THE ADVERSE RISK OF FLT3 POSITIVIVITY IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA? | Sorcha Ni Loingsigh | ![]() |
![]() |
|||
376-P | RITUXIMAB-BASED TREATMENTS FOLLOWED BY ADOPTIVE CELLULAR THERAPIES FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
378-P | A GENETIC VARIANT IN THE CD53 INTRON FUNCTIONALLY PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED BONE MARROW TRANSPLANTATION | Akiyoshi Takami | ![]() |
![]() |
|||
379-P | RELATIONSHIP BETWEEN INFUSION FEVER FOLLOWING PERIPHERAL BLOOD STEM CELL AND PERI-ENGRAFTMENT SYNDROME IN PEADIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION | YAO CHEN | ![]() |
![]() |
|||
381-P | STENOTROPHOMONAS MALTOPHILIA INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION -RISK FACTORS AND THERAPEUTIC STRATEGIES- | Shiratori Souichi | ![]() |
![]() |
|||
387-P | ERYTHROPOIETIN IMPROVES BRAIN DEVELOPMENT IN SHORT-TERM HY0POXIA IN RAT EMBRYO CULTURES | Yasemin Altuner Torun | ![]() |
![]() |
|||
388-P | DISULFIRAM/COPPER COMPLEX COULD ELIMINATE RAJI CELLS IN VITRO AND VIVO THROUGH ACTIVATION OF OXIDATIVE STRESS AND INHIBITION OF NRF2 AND NF-?B | Bing Xu | ![]() |
![]() |
|||
391-P | THE SAFETY PROFILE OF DEFERASIROX REMAINS CONSISTENT AS NON-TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS APPROACH THE TARGET LIVER IRON CONCENTRATION OF 3 MG FE/G DW FOR INTERRUPTING CHELATION | Germanicus Hansa-Wilkinson | ![]() |
![]() |
|||
392-P | PROGNOSTIC CMR PARAMETERS FOR HEART FAILURE AND ARRHYTHMIAS IN A LARGE COHORT OF WELL TREATED THALASSEMIA MAJOR PATIENTS | Antonella Meloni | ![]() |
![]() |
|||
393-P | IMPACT OF MONITORING WITH LIVER MRI-R2 ON LIVER IRON BURDEN AND DEVELOPMENT OF ENDOCRINOPATHIES: A RETROSPECTIVE AUDIT | Stephanie Ko | ![]() |
![]() |
|||
394-P | MYOCARDIAL FIBROSIS BY CMR LGE IN A LARGE COHRT OF PEDIATRIC THALASSEMIA MAJOR PATIENTS | Antonella Meloni | ![]() |
![]() |
|||
395-P | CMR SURVEY IN A LARGE COHORT OF TI PATIENTS CATEGORIZED IN DIFFERENT TRANSFUSIONAL REGIMENS | Antonella Meloni | ![]() |
![]() |
|||
396-P | EVALUATION OF GLYCAEMIC ABNORMALITIES IN ?ETA THALASSEMIA MAJOR USING CONTINUOUS GLUCOSE MONITORING SYSTEM AND ORAL GLUCOSE TOLERANCE TEST | Mohamed AbdelDaem Mohamed Yassin | ![]() |
![]() |
|||
398-P | EFFECTS OF THE ANTI RANK LIGAND DENUSOMAB ON BETA THALASSEMIA MAJOR-INDUCED OSTEOPOROSIS | Mohamed AbdelDaem Mohamed Yassin | ![]() |
![]() |
|||
399-P | REFERENCE RANGES FOR BIVENTRICULAR VOLUMES AND EJECTION FRACTION AND FOR LEFT VENTRICULAR MASS IN ADULT THALASSEMIA INTERMEDIA PATIENTS WITHOUT MYOCARDIAL IRON OVERLOAD | Antonella Meloni | ![]() |
![]() |
|||
400-P | CLINICAL EVOLUTION IN FOUR CARRIERS OF BETA GLOBIN LOCUS DELETIONS | Felix De la Fuente | ![]() |
![]() |
|||
401-P | PITUITARY MRI IN CORRELATION WITH IRON OVERLOAD AND HYPOGONADISM IN YOUNG THALASSEMIA MAJOR PATIENTS | Amira Adly | ![]() |
![]() |
|||
402-P | HBH CONSTANT SPRING DISEASE (HBHCS) HAS LOWER SERUM FERRITIN RELATIVE TO LIVER IRON CONCENTRATION (LIC) COMPARED TO DELETIONAL HBH DISEASE: IMPORTANCE OF LIC MEASUREMENT IN HBHCS | Ai Leen Ang | ![]() |
![]() |
|||
403-P | AN AUTOMATIC METHOD FOR MYOCARDIAL T2 CURVE FITTING IN THALASSEMIA PATIENTS WITH SEVERE IRON OVERLOAD | Antonella Meloni | ![]() |
![]() |
|||
404-P | MOVEMENT ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA MAJOR PATIENTS | Antonella Meloni | ![]() |
![]() |
|||
406-P | Mortality sickle cell diseaserisk factors in a Dutch cohort | Marein Schimmel | ![]() |
![]() |
|||
407-P | PRASUGREL IN CHILDREN WITH SICKLE CELL DISEASE: PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS FROM AN OPEN-LABEL, ADAPTIVE-DESIGN, DOSE-RANGING STUDY | Julie Sherman | ![]() |
![]() |
|||
410-P | NEWBORN SCREENING FOR SICKLE CELL DISEASE IN BRUSSELS, A PROGRAM WITH AN ONGOING CLINICAL OUTCOME IMPROVEMENT | Phu-Quoc L | ![]() |
![]() |
|||
411-P | ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE INTRONE4 VNTR POLYMORPHISM IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT ?-THALASSEMIA MAJOR: RELATION TO CARDIO-VASCULAR COMPLICATIONS | Azza Tantawy | ![]() |
![]() |
|||
412-P | ANTENATAL SCREENING PROGRAMME FOR HAEMOGLOBINOPATHY IN A LOW PREVALENCE AREA: IS IT EFFECTIVE? | ANANDIKA LIYANAGE | ![]() |
![]() |
|||
413-P | FG4592, A NOVEL INHIBITOR OF THE PROLYL HYDROXYLASE OF HYPOXIA-INDUCIBLE FACTOR (HIF-PH) ELICITED LINEAR-EXPONENTIAL DOSE-RESPONSE PROFILE ON PLASMA ERYTHROPOIETIN (EPO) LEVELS | Xia Chen | ![]() |
![]() |
|||
415-P | DEVELOPMENT OF A LABORATORY PATHWAY TO ASSIST THE DIAGNOSIS OF HEREDITARY HAEMOCHROMATOSIS IN PRIMARY CARE | Catherine Ogilvie | ![]() |
![]() |
|||
418-P | INTRAVENOUS IRON THERAPY FOR TREATMENT OF ANEMIA DURING PREGNANCY IS ASSOCIATED WITH IMPROVED MATERNAL QUALITY OF LIFE, LESS POSTNATAL DEPRESSION AND LONGER BREASTFEEDING | Alhossain Khalafallah | ![]() |
![]() |
|||
420-P | STUDY OF IRON STATUS AS A CONTRIBUTING FACTOR TO ANEMIA IN PEDIATRIC CANCER PATIENTS | Azza Tantawy | ![]() |
![]() |
|||
424-P | FOUR MEASURES TO REDUCE THE RATE OF HEALTH CARE-ASSOCIATED BLOODSTREAM INFECTIONS RELATED TO THE USE OF NEEDLESS MECHANICAL VALVE CONNECTORS IN LONG-TERM CENTRAL VENOUS CATHETERS | Nélson Domingues | ![]() |
![]() |
|||
427-P | A RETROSPECTIVE STUDY OF THE RELATIONSHIP BETWEEN VITAMIN D SUPPLEMENTATION AND THE RISK OF FEBRILE NEUTROPENIA(FN) IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES IN EAST KENT HOSPITALS(EKUFHT) | Salah-Eldin Alhassan | ![]() |
![]() |
|||
428-P | INFECTIONS CAUSED BY CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Maria Stamouli | ![]() |
![]() |
|||
431-P | ABNORMAL SPLEEN FUNCTION ASSESSED BY THE STUDY OF PITS AND SUBMEMBRANOUS VACUOLES IN ERYTHROCYTES IN PATIENTS WITH SPLENOMEGALY OF DIFFERENT ETIOLOGY | EVARIST FELIU | ![]() |
![]() |
|||
432-P | NEUTROPENIC ENTEROCOLITIS AND VANCOMYCIN RESISTANT ENTEROCOCCUS AS PREDISPOSING FACTOR | Elif Gulsum Umit | ![]() |
![]() |
|||
433-P | ANAEROBIC BLOODSTREAM INFECTIONS AMONG HAEMATOLOGICAL CANCER PATIENTS: EPIDEMIOLOGY AND OUTCOME. RESULTS OF AN 8-YEAR SURVEILLANCE PROGRAM AT A SINGLE INSTITUTION | Chiara Cattaneo | ![]() |
![]() |
|||
434-P | COMPARISON OF THE BD GENEOHMVANR ASSAY TO CULTURE FOR IDENTIFICATION OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN RECTAL AND STOOL SPECIMENS IN PEDIATRIC MALIGNANCY PATIENTS | yaman yntem | ![]() |
![]() |
|||
435-P | REASONS FOR TREATMENT SEEKING DELAY IN NEUTROPENIC SEPSIS | Marc Talbot | ![]() |
![]() |
|||
436-P | CEFEPIME-INDUCED ENCEPHALOPATHY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: CLINICAL FEATURES AND RISK FACTORS | Tomotaka Ugai | ![]() |
![]() |
|||
438-P | USEFULNESS OF GALACTOMANNAN ASSAY IN BRONCHOALVEOLAR LAVAGE SAMPLES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND RISK OF INVASIVE PULMONARY ASPERGILLOSIS. | Rafael Del Orbe Barreto | ![]() |
![]() |
|||
439-P | RISK FACTORS RELATED TO MORTALITY IN HEMATOLOGICAL PATIENTS ADMITTED TO INTENSIVE CARE UNIT (ICU) | Sandra Iraheta | ![]() |
![]() |
|||
442-P | DIAGNOSTIC EFFICACY OF GALACTOMANNAN ASSAY AND COMPUTERIZED CHEST TOMOGRAPHY IN INVASIVE ASPERGILLOSIS OF FEBRILE NEUTROPENIC CHILDREN | Gonul Aydogan | ![]() |
![]() |
|||
443-P | VESICLES OBSERVED IN LEUCOREDUCED AND NON LEUCOREDUCED CONCENTRATED RED BLOOD CELLS BY MEANS OF ADVANCED MICROSCOPES: POSSIBLE RELATION TO THE STORAGE LESION | Dimosthenis Stamopoulos | ![]() |
![]() |
|||
445-P | Alloantibody formation is increased in Sickle Cell Disease patients compared to the general population | Joep Sins | ![]() |
![]() |
|||
446-P | THE ROLE OF BLOOD TRANSFUSION IN BETA-THALASSEMIA: AN EX VIVO STUDY OF HEMOSTATIC PARAMETERS | Alice Trinchero | ![]() |
![]() |
|||
448-P | TRANSCRIPTIONAL PROFILING OF HUMAN ERYTHROID PROGENITORS FROM G-CSF MOBILIZED AND NONMOBILIZED PERIPHERAL BLOOD | Vladan Cokic | ![]() |
![]() |
|||
450-P | MATERNAL AND FETAL OUTCOMES IN PREGNANT PATIENTS WITH SICKLE CELL DISEASE WHO APPLIED PROPHYLACTIC RED BLOOD CELL EXCHANGE PROCEDURE | Ilknur Kozanoglu | ![]() |
![]() |
|||
452-P | ANCESTIM VERSUS PLERIXAFOR FOR THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS | Adrian Tempescul | ![]() |
![]() |
|||
453-P | BONE MARROW ASPIRATE MORPHOLOGIC, IMMUNOPHENOTYPIC AND CYTOGENETIC EVALUATION IN RELATED DONORS PRIOR TO HEMATOPOIETIC STEM CELL DONATION | Raffaella Milani | ![]() |
![]() |
|||
454-P | THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY | Ghazi Alotaibi | ![]() |
![]() |
|||
456-P | FAILURE ON MAINTAINING HAEMOGLOBIN LEVEL AFTER TRANSFUSION IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS RELATED TO ERYTHROCYTE ALLOANTIBODY AND AUTOANTIBODY PRODUCTION: PROPORTION AND REL | Andree Kurniawan | ![]() |
![]() |
|||
457-P | EFFECT OF USING LEUKOSTOP FILTER DURING BLOOD TRANSFUSION ON PULMONARY FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR | Iman Ragab | ![]() |
![]() |
|||
458-P | PLATELET TRANSFUSIONS IN HAEMATOLOGY PATIENTS | bachra choufi | ![]() |
![]() |
|||
459-P | THE EFFECTIVENESS OF PLATELETS TRANSFUSIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML) DURING INDUCTION CHEMOTHERAPY (IC). | Bulgan Davaasambuu | ![]() |
![]() |
|||
460-P | MEASUREMENT OF IRON CONCENTRATION IN HAIR AS AN INDICATOR OF BODY IRON LOAD | Yasemin Altuner Torun | ![]() |
![]() |
|||
461-P | REVIEW AND DESIGN OF A NEW BLOOD BOOKING PROTOCOL FOR EACH SURGERY AND A RESTROSPECTIVE STUDY OF THE DIRECT EXPENSE DECREASE WITH THE NEW PROTOCOL | Angel Pereda Vicandi | ![]() |
![]() |
|||
462-P | A CANADIAN TALE OF TWO BLOOD GROUPS | Conal McConville | ![]() |
![]() |
|||
466-P | RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH LOW-DOSE RITUXIMAB (LD RTX) IN SEVERE OR REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER PROSPECTIVE CLINICAL TRIAL | MING HOU | ![]() |
![]() |
|||
470-P | RITUXIMAB VERSUS SPLENECTOMY IN PERSISTENT OR CHRONIC ADULT PRIMARY IMMUNE THROMBOCYTOPENIA: AN ADJUSTED COMPARISON OF MORTALITY AND MORBIDITY | Guillaume Moulis | ![]() |
![]() |
|||
471-P | EVALUATION OF THE IMMATURE PLATELET FRACTION IN THE DIAGNOSIS AND PROGNOSIS OF CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA | Amira Adly | ![]() |
![]() |
|||
472-P | THALIDOMIDE CORRECTS IMPAIRED MESENCHYMAL STEM CELL FUNCTION IN INDUCING TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA | JUN PENG | ![]() |
![]() |
|||
473-P | DISEASE PROGRESSION, TREATMENT PATTERNS, AND CO-MORBID BURDEN AMONG ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UPDATED RESULTS FROM THE UNITED KINGDOM ITP REGISTRY | Dimitri Bennett | ![]() |
![]() |
|||
474-P | THROMBOEMBOLIC EVENTS IN PATIENTS WITH ADULT CHRONIC IMMUNE THROMBOCTOPENIA (ITP) TREATED WITH ELTROMBOPAG | shojiro Takagi | ![]() |
![]() |
|||
475-P | MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA IN JAPAN: PATIENT AND HEMATOLOGIST PERSPECTIVES | Norio Komatsu | ![]() |
![]() |
|||
476-P | D-DIMER LEVELS IN ACUTE IDIOPATHIC AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA | Andrew Grosset | ![]() |
![]() |
|||
477-P | THROMBOCYTOPENIA IN PREGNANCY: OUR EXPERIENCE AT THE NATIONAL MATERNITY HOSPITAL | MATIAS DIAZ | ![]() |
![]() |
|||
478-P | MONITORING ANTIPLATELET THERAPY : ACTIVITY OF ADENOSINE DIPHOSPHATE RECEPTOR INHIBITORS IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION | Marian Fedor | ![]() |
![]() |
|||
479-P | ANALYSIS OF RETICULATED PLATELETS IN THE ROUTINE CLINICAL PRACTICE USING THE CELL-DYN SAPPHIRE INSTRUMENT | Hans Wadenvik | ![]() |
![]() |
|||
481-P | THE ROLE OF OXIDATIVE STRESS IN CHILDREN WITH ACUTE AND CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA | Erol Erduran | ![]() |
![]() |
|||
482-P | PILOT OBSERVATIONAL STUDY OF ROTATIONAL THROMBOELASTOMETRY (ROTEM) TO PREDICT BLEEDING RISK IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ATHENA STUDY) | Lise Estcourt | ![]() |
![]() |
|||
483-P | AUTOCRINE AMPLIFICATION OF INTEGRIN aIIBb3 ACTIVATION AND PLATELET ADHESIVE RESPONSES BY DEOXYRIBOSE-1-PHOSPHATE | Dina Vara | ![]() |
![]() |
|||
484-P | INCREASED CIRCULATING MICROPARTICLES COEXPRESSING ENDOTHELIAL AND PLATELET MARKERS IN ISCHEMIC CEREBRAL STROKE | Ghada Ezzat | ![]() |
![]() |
|||
485-P | LOW MOLECULAR WEIGHT HEPARIN (LMWH) FOR PRIMARY THROMBOPROPHYLAXIS OF AMBULATORY PATIENTS WITH SOLID CANCER SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | Anat Gafter-Gvili | ![]() |
![]() |
|||
486-P | PLATELET COUNTS DECREASE WITH INCREASING LUPUS-LIKE ANTICOAGULANT RATIOS, IRRESPECTIVE OF ANTIPHOSPHOLIPID SYNDROME CRITERIA | Marta Pereira | ![]() |
![]() |
|||
487-P | REDOX-DEPENDENT ANGIOGENESIS BY NUCLEOSIDE DERIVATIVES OF DEOXYRIBOSE-1-PHOSPHATE | Dina Vara | ![]() |
![]() |
|||
488-P | THE JAK2 V617F MUTATION IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS IS ASSOCIATED WITH AN INCREASED RISK OF RECURRENCE | Valerio De Stefano | ![]() |
![]() |
|||
490-P | ADVANTAGES AND DISADVANTAGES OF INCORPORATING C-REACTIVE PROTEIN LEVELS, AGE AND D-DIMER LEVELS IN DIAGNOSING PULMONARY EMBOLISM | Meindert Crop | ![]() |
![]() |
|||
491-P | EVALUATING ACQUIRED DISORDERS OF PROTEIN C SYSTEM IN PATIENTS ON VITAMIN K ANTAGONISTS TREATMENT BY THE CALIBRATED AUTOMATED THROMBOGRAM | Veronika Shmeleva | ![]() |
![]() |
|||
493-P | THE ROLE OF ANTICOAGULANT THERAPIES ON COAGULOPATHY (DISSEMINATED INTRAVASCULAR COAGULATION) IN PATIENTS WITH HEMOLYTICUREMIC SYNDROME AFTER INFECTION WITH ENTEROHEMORRHAGIC ESCHERICHIA COLI O111. | Jun Murakami | ![]() |
![]() |
|||
494-P | UNEXPECTED FATAL PULMONARY EMBOLISM FOUND AT FORENSIC AUTOPSIES | Mariana Villegas Scivetti | ![]() |
![]() |
|||
496-P | ANTITHROMBOTIC PROPHYLAXIS IN PREGNANT WOMEN WITH ANTITHROMBIN CONGENITAL DEFICIENCY IS EFFECTIVE IN PREVENTING ADVERSE OUTCOMES | Valerio De Stefano | ![]() |
![]() |
|||
497-P | HIGH PREVALENCE OF PROTEIN S DEFICIENCY IN THAI POPULATION | Ponlapat Rojnuckarin | ![]() |
![]() |
|||
498-P | MANAGEMENT OF EXCESSIVE ANTICOAGULATION IN PATIENTS TREATED WITH ACENOCOUMAROL, A VITAMIN K ANTAGONIST. | Jesus Cesar | ![]() |
![]() |
|||
499-P | GENETIC POLYMORPHISMS RELATED TO HEMOSTASIS AND THEIR ASSOCIATION WITH PRIMARY RECURRENT PREGNANCY LOSS | Elvira Guerra-Shinohara | ![]() |
![]() |
|||
500-P | HIGH ON-TREATMENT PLATELET REACTIVITY: NOT AN ISOLATED PROBLEM | Martin Jakl | ![]() |
![]() |
|||
501-P | EVALUATION OF PIVKA-II AS A PREDICTOR MARKER FOR PORTAL VEIN THROMBOSIS IN HEPATOCELLULAR CARCINOMA PATIENTS | Maryse Ayoub | ![]() |
![]() |
|||
503-P | PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE SUCCESSFULLY UTILIZED IN HAEMATOLOGICAL PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM CELL TRANSPLANTATION | Alessandra Malato | ![]() |
![]() |
|||
504-P | PICC INSERTION AND MANAGEMENT IN HEMATOLOGY PATIENTS: 5 YEARS PROSPECTIVE STUDY THE CAGLIARIS DEPARTMENT OF HAEMATOLOGY | Daniele Derudas | ![]() |
![]() |
|||
505-P | A NEW SCORE TO DETERMINE THE PROBABILITY OF FINDING AN HLA IDENTICAL UNRELATED DONOR: A VALIDATED EFFICIENT TIME AND COST SAVING METHOD | Mauricette Michallet | ![]() |
![]() |
|||
506-P | ESTIMATES OF BURDEN OF DISEASE ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKEMIA IN UK AND US | Izabela Kucmin | ![]() |
![]() |
|||
511-P | THE IMPACT OF UNRESTRICTED FUNDING ON HAEMATO-ONCOLOGY TREATMENT CHOICE | Tony Todd | ![]() |
![]() |
|||
512-P | PATIENT SAFETY AND CLINICAL EFFICIENCY GAINS FOLLOWING IMPLEMENTATION OF AN INTEGRATED HEALTH INFORMATION SYSTEM IN EAST LONDON. | Ciara Freeman | ![]() |
![]() |
|||
513-P | PHARMACOLOGICAL DRUG EXPENDITURE OF FIRST-LINE INDOLENT NON-HODGKIN LYMPHOMAS IN SPAIN | Juan Manuel Collar | ![]() |
![]() |
|||
514-P | A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA | Amin Haiderali | ![]() |
![]() |
|||
515-P | A COST-BENEFIT ASSESSMENT OF TREATMENT (TX) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: AN EFFICIENCY FRONTIER APPROACH | Shien Guo | ![]() |
![]() |
|||
518-P | A CALL FOR A STANDARDISED MEASUREMENT OF HAEMOGLOBIN IN THE REPUBLIC OF IRELAND | Jennifer O Sullivan | ![]() |
![]() |
|||
519-P | DEMAND MANAGEMENT IN A UNIVERSITY LABORATORY IN THE WEST OF IRELAND; THE FINANCIAL BENEFIT OF DISTRIBUTION OF LOCAL GUIDELINES FOR VITAMIN B12 TESTING. | Aoibheann Ni Chonfhaola | ![]() |
![]() |
|||
617-P | A COHORT STUDY OF POST-RELAPSE/RESISTANCE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA | TAMARA INTERMESOLI | ![]() |
![]() |
|||
618-P | A SEQUENTIAL USE OF TKI, CHEMOTHERAPY AND TRANSPLANT IS ASSOCIATED WITH HIGH COMPLETE REMISSION RATES, DISEASE-FREE AND OVERALL SURVIVAL IN ADULT PH ALL. RESULTS OF THE GIMEMA 0904 PROTOCOL | Sabina Chiaretti | ![]() |
![]() |
|||
619-P | Comorbidity impacts on complete remission rate in elderly patients with acute lymphoblastic leukemia | Colombe Saillard | ![]() |
![]() |
|||
620-P | CLL PATIENTS CARRYING 13q DELETION SHOW CLINICAL HETEROGENEITY ACCORDING TO IGHV MUTATIONAL STATUS AND CD38 EXPRESSION | Andrea Visentin | ![]() |
![]() |
|||
621-P | COMPARABLE OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION AS POST-REMISSION THERAPY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: INTERIM ANALYSIS OF PROSPECTIVE STUDY | Dae-Young Kim | ![]() |
![]() |
|||
623-P | MRD LEVEL ANALYSIS IN ADULT ALL PATIENTS. ANALYSIS OF THE CZECH LEUKEMIA STUDY GROUP FOR LIFE (CELL) | Cyril álek | ![]() |
![]() |
|||
624-P | FLUDARABINE, ARA-C AND LIPOSOMAL DAUNORUBICIN (FLAD) PLUS HEMOPOIETIC STEM CELL TRANSPLANT (HSCT) AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA. | Marino Clavio | ![]() |
![]() |
|||
626-P | CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL) : THE BOLOGNA EXPERIENCE | mariachiara abbenante | ![]() |
![]() |
|||
627-P | ENCOURAGING SURVIVAL IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - RESULTS OF RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GROUP | Elena Parovichnikova | ![]() |
![]() |
|||
629-P | FOUR YEARS EXPERIENCE WITH HYPER-CVAD TREATMENT OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN SWEDEN. POPULATION-BASED DATA. | Piotr Kozlowski | ![]() |
![]() |
|||
631-P | ADULT MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO THE WHO 2008 CLASSIFICATION A SINGLE CENTER EXPERIENCE | Claudia Moreira | ![]() |
![]() |
|||
632-P | INTEGRATING ALTERNATIVE DONORS ALLOWS BEST OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTRE STUDY | Barbara Forno | ![]() |
![]() |
|||
633-P | OBESITY, INSULIN RESISTANCE AND ADIPOKINES IN SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. | Trkiz Grsel | ![]() |
![]() |
|||
634-P | ZAP70 GENE EXPRESSION MAY BE A PROGNOSTIC FACTOR FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Bing Xu | ![]() |
![]() |
|||
638-P | EFFECTS OF PROPHYLACTIC CRANIAL RADIOTHERAPY ON GROWTH HORMONE SECRETION OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA | Gonul Aydogan | ![]() |
![]() |
|||
639-P | THE IMPACT OF RISK STRATIFICATION BY EARLY BONE-MARROW RESPONSE AND FCM-MRD IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA (A SINGLE INSTITUTION EXPERIENCE IN AZIZA OTHMANA HOSPITAL, TUNIS, TUNISIA). | BEN ABDENNEBI Yosr | ![]() |
![]() |
|||
641-P | IDENTIFICATION OF NOVEL GENETIC ALTERATIONS BY WHOLE-TRANSCRIPTOME SEQUENCING IN INFANTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA | Marco Togni | ![]() |
![]() |
|||
643-P | ALTERED GENES DOWNSTREAM OF MYCN IN ACUTE MYELOID LEUKEMIA IN ZEBRAFISH BY RETINOIC ACID AND VALPROIC ACID | Li-Jing SHEN | ![]() |
![]() |
|||
645-P | EXPRESSION, REGULATION AND FUNCTIONAL ROLES OF THE CHEMOKINE RECEPTOR CXCR7 IN ACUTE MYELOID LEUKAEMIA CELLS | Deog-Yeon Jo | ![]() |
![]() |
|||
646-P | INTERLEUKIN-3 RECEPTOR ALPHA CHAIN (CD123) AS A MARKER FOR LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA AND ITS RELATION TO DISEASE PROGRESSION | Hanan Alwakeel | ![]() |
![]() |
|||
647-P | EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION | SANDRA DOLZ GIMÉNEZ | ![]() |
![]() |
|||
648-P | MUTATIONS IN RUNX1 AND NPM1 COMBINED WITH IMBALANCES OF CHROMOSOME 21 ARE PREDICTIVE FOR PROGRESSION OF AML | Katya Gancheva | ![]() |
![]() |
|||
649-P | PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA | Marta Llop García | ![]() |
![]() |
|||
651-P | CLINICAL AND HEMATOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA WITH REARRANGEMENTS OF EVI1 OR PRDM16 | marion eveillard | ![]() |
![]() |
|||
653-P | IMPACT OF THE E3 UBIQUITIN LIGASE TRAF2 ON TNF-?-INDUCED APOPTOSIS IN A CELL MODEL OF FLT3-ITD-POSITIVE AML | Sebastian Scholl | ![]() |
![]() |
|||
654-P | PLUMBAGIN ENHANCED TRAIL-INDUCED APOPTOSIS OF KASUMI-1 CELLS IN NOD / SCID MICE | Li-Gen Liu | ![]() |
![]() |
|||
658-P | IMPLICATIONS OF MIR-10 IN CHEMOTHERAPY RESPONSE OF NPM1 MUTATED AML | ramiro garzon | ![]() |
![]() |
|||
660-P | SYNERGISTIC EFFECTS OF HSP70 AND HSP90 INHIBITORS IN PRIMARY HUMAN ACUTE MYELOID LEUKEMIA CELLS | Hkon Reikvam | ![]() |
![]() |
|||
662-P | IMPROVEMENT, BUT STILL POOR PROGNOSIS FOR ESTONIAN PATIENTS COMPARED TO A WELL-DEFINED REGION OF WESTERN SWEDEN, A POPULATION BASED STUDY OF ACUTE DE NOVO LEUKEMIA PATIENTS AGED 16-64 YEARS | Erik Hulegrdh | ![]() |
![]() |
|||
663-P | PROGNOSTIC IMPACT OF NPM1, IDH1/2 AND DNAH11 GENE MUTATIONS ON NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA PATIENTS NOT HARBORING FLT3/ITD MUTATION | Yeo-Kyeoung Kim | ![]() |
![]() |
|||
664-P | ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA | Benedetto Bruno | ![]() |
![]() |
|||
667-P | SYSTEMIC VERSUS LOCALIZED THERAPEUTIC APPROACH FOR ISOLATED MYELOID SARCOMA: META-ANALYSIS OF INDIVIDUAL PATIENT DATA | Darko Antic | ![]() |
![]() |
|||
669-P | LOW MDR1 AND BAALC EXPRESSION IDENTIFIES A NEW SUBGROUP OF ADULT CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH A FAVORABLE OUTCOME | Xutao Guo | ![]() |
![]() |
|||
670-P | THE SURFACE MOLECULAR SIGNATURE OF LEUKEMIC CELLS WAS ASSOCIATED WITH NPM1 AND FLT3-ITD MUTATIONS IN ACUTE MYELOID LEUKEMIA | SuJun Gao | ![]() |
![]() |
|||
671-P | IMPACT OF DAY 14 BONE MARROW EXAMINATION ON RE-INDUCTION DECISION AND PREDICTION OF COMPLETE RESPONSE IN ACUTE MYELOGENOUS LEUKEMIA (AML) | Aamer Aleem | ![]() |
![]() |
|||
672-P | ADVERSE PROGNOSTIC SIGNIFICANCE OF FLT3 MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA | mirjana mitrovic | ![]() |
![]() |
|||
675-P | PERIPHERAL BLOOD BLASTS ON DAY 7 OF INITIAL INDUCTION THERAPY PREDICT RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | SuJun Gao | ![]() |
![]() |
|||
676-P | PROGNOSTIC VALUE OF TH17 CELLS IN ACUTE LEUKEMIA | Manal Salah Eldin | ![]() |
![]() |
|||
677-P | STUDIES ON BCR AND TLR SIGNALLING IN AGGRESSIVE CLL- THE CASE OF STEREOTYPED SUBSET 1 | Ann-Charlotte Bergh | ![]() |
![]() |
|||
678-P | THE PHOSPHO-PROTEOMIC PROFILE OF CD49D-EXPRESSING CIRCULATING CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IS CONSISTENT WITH CONSTITUTIVE RECEPTORIAL ENGAGEMENT BY BLOOD-BORNE LIGANDS | Dania Benedetti | ![]() |
![]() |
|||
682-P | SINGLE CELL NETWORK PROFILING (SCNP) ANALYSIS REVEALS DYSFUNCTIONAL SIGNALING WITHIN THE TH17 AXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Michelle Atallah | ![]() |
![]() |
|||
684-P | EXPRESSION OF ZAP-70 IN CLL ACTIVATES NF-KB SIGNALING | Valerie Pede | ![]() |
![]() |
|||
685-P | THE PRO-APOPTOTIC MIR-132212/SIRT1/TP53 AXIS IS ACTIVATED UPON B-CELL RECEPTOR TRIGGERING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS | Riccardo Bomben | ![]() |
![]() |
|||
686-P | HETEROGENEOUS FUNCTIONAL EFFECTS OF CONCOMITANT B CELL RECEPTOR AND TOLL-LIKE RECEPTOR STIMULATION IN CLL WITH MUTATED VERSUS UNMUTATED IMMUNOGLOBULIN GENES | Stavroula Ntoufa | ![]() |
![]() |
|||
687-P | IGG-SWITCHED CLL HAS A DISTINCT IMMUNOGENETIC SIGNATURE FROM THE COMMON MD VARIANT: ONTOGENETIC IMPLICATIONS | Anna Vardi | ![]() |
![]() |
|||
689-P | ABERRANT EXPRESSION OF PD-1 IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT FROM BCR SINGLING AND PDCD1 GENE POLYMORPHISM | Maciej Grzywnowicz | ![]() |
![]() |
|||
695-P | A NEW ONCOGENIC ROLE OF BCR/ABL-OOF IN CHRONIC MYELOID LEUKAEMIA PATHOGENESIS | Cristina Panuzzo | ![]() |
![]() |
|||
697-P | MICROVESICLES TRANSCRIPTOME REFLECTS PHYSIOLOGICAL CONDITIONS OF LEUKEMIC PARENTAL CELLS | Gloria Milani | ![]() |
![]() |
|||
698-P | THE REFERENCE STANDARD FOR BCR-ABL TRANSCRIPT MONITORING IS IMPORTANT TO DEFINE CMR IN CML PATIENTS AND TO TEST THE RQ-PCR METHOD PERFORMANCES | Rodica TALMACI | ![]() |
![]() |
|||
700-P | IDENTIFICATION AND FOLLOW-UP OF TWO NEW RARE E8A2 BCR-ABL FUSION GENES | Sarah Huet | ![]() |
![]() |
|||
702-P | EVALUATION OF TOB1 GENE EXPRESSION IN CML PATIENTS AND BLOOD DONOR AND THE EFFECT OF GENE SILENCING IN BCR-ABL CELL LINE | CINTIA MASCARENHAS | ![]() |
![]() |
|||
705-P | PATTERNS OF ABL KD MUTATION IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA | Hawk Kim | ![]() |
![]() |
|||
706-P | COMPARISON OF NON AUTOMATED BCR-ABL1 RT-QPCR WITH THE XPERT BCR-ABL MONITOR TM ASSAY | Stephanie Dulucq | ![]() |
![]() |
|||
711-P | LONG-TERM SURVIVAL OUTCOME AND PROGNOSIS IN 2277 PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ALLOCATED TO FIRST-LINE IMATINIB TREATMENT NEW RESULTS FROM THE EUTOS IN-STUDY REGISTRY | Markus Pfirrmann | ![]() |
![]() |
|||
713-P | DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE | Helen White | ![]() |
![]() |
|||
714-P | CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES (BCR-ABL1 =10 AT 3 MONTHS AND =1 6 MONTHS) AS A PREDICTOR FOR LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB | Sung-Eun Lee | ![]() |
![]() |
|||
716-P | HEPATITIS B VIRUS REACTIVATION IN CHRONIC MYELOID LEUKEMIA TREATED WITH VARIOUS TYROSINE KINASE INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY | Sung-Hyun Kim | ![]() |
![]() |
|||
717-P | EARLY AND DEEP RESPONSES TO IMATINIB PREDICT NOT ONLY COMPLETE MOLECULAR RESPONSE BUT ALSO THE PROBABILITY FOR MAINTAINING THE RESPONSE. | Valentín García-Gutiérrez | ![]() |
![]() |
|||
720-P | IN CML PATIENTS TREATED FRONTLINE WITH IMATINIB, WITH A BCR-ABL RATIO HIGHER THAN 10 AT 3 MONTHS, THE CHANGE TO A 2ND GTKI IS ASSOCIATED WITH IMPROVEMENT OF CYTOGENETIC RESPONSE, BUT NOT WITH MMR | LUIS FELIPE CASADO MONTERO | ![]() |
![]() |
|||
721-P | CLINICAL AND BIOLOGICAL FEATURES OF BLAST CRISIS (BC) IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) IN THE TKIS ERA: EXPERIENCES IN CLINICAL PRACTICE | Antonella Russo Rossi | ![]() |
![]() |
|||
722-P | REVERSIBLE LYMPH NODE FOLLICULAR HYPERPLASIA ASSOCIATED WITH DASATINIB TREATMENT FOR CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE | Clémence Roux | ![]() |
![]() |
|||
723-P | Descriptive study of CML patients in major molecular response (MMR) with an evaluation of clinical and therapeutic characteristics leading to the conversion into a complete molecular response (CMR) | Mauricette Michallet | ![]() |
![]() |
|||
726-P | EUTOS CML PROGNOSTIC SCORING SYSTEM PREDICTS ELN-BASED EVENT-FREE SURVIVAL BETTER THAN EURO/HASFORD AND SOKAL SYSTEMS IN CHRONIC PHASE CML PATIENTS RECEIVING FRONTLINE IMATINIB MESYLATE | Nilgun Sayinalp | ![]() |
![]() |
|||
728-P | BONE MARROW IMAGING OF HUMERAL AND FEMORAL MARROW BY MULTI-DETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH APLASTIC ANEMIA AND HYPOPLASTIC MDS | Tomotaka Ugai | ![]() |
![]() |
|||
730-P | BONE MARROW SCREENING FOR MYELODYSPLASIA-RELATED CHANGES AND ABERRANT LYMPHOID POPULATIONS USING ONE TUBE, FOURTEEN ANTIBODY-TEN COLOR FLOW CYTOMETRY PANEL | Anna Porwit | ![]() |
![]() |
|||
731-P | PLATELET COUNT AND TRANSFUSION-DEPENDENCY AFFECT OVERALL SURVIVAL IN PATIENTS WITH REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS (RARS-T) | Gregory Kaufman | ![]() |
![]() |
|||
732-P | A PROSPECTIVE PHASE II STUDY OF ATG-CYCLOSPORINE A FOR ADULT SEVERE APLASTIC ANEMIA: MEDIAN 8-YEAR FOLLOW-UP DATA | Hawk Kim | ![]() |
![]() |
|||
733-P | IMPACT OF THE PROLIFERATION INDEX OF SPECIFIC BONE MARROW CELL COMPARTMENTS FROM MYELODYSPLASTIC SYNDROMES IN THE MONITORIZATION OF THE DISEASE: A PILOT STUDY | Sergio Matarraz | ![]() |
![]() |
|||
734-P | BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY | Claudio Cerchione | ![]() |
![]() |
|||
736-P | LONG DURATION OF RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES. MULTICENTER RETROSPECTIVE STUDY OF 36 PATIENTS | Carlo Finelli | ![]() |
![]() |
|||
737-P | PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE | cristina clissa | ![]() |
![]() |
|||
739-P | REAL WORLD USE OF AZACITIDINE IN ELDERLY PATIENTS WITH MDS/AML THE SCOTTISH EXPERIENCE | Kirstin Lund | ![]() |
![]() |
|||
740-P | MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE | Dawn Lee | ![]() |
![]() |
|||
741-P | ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELODYSPLASTIC SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE | Claudio Cerchione | ![]() |
![]() |
|||
743-P | RISK SCORING SYSTEM USING IPSS-R, LDH AND PERFORMANCE STATUS TO PREDICT THE OUTCOMES OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS | Sang Kyun Sohn | ![]() |
![]() |
|||
744-P | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE: DIAGNOSTIC AND CLASSIFICATION OF 103 BRAZILIAN PATIENTS | ANA PAULA AZAMBUJA | ![]() |
![]() |
|||
745-P | ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT | Claudio Cerchione | ![]() |
![]() |
|||
746-P | COMPARISON OF IPSS AND R-IPSS IN A SINGLE UNIT PATIENT COHORT | Francesca Pierdomenico | ![]() |
![]() |
|||
747-P | DOES REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS? | Zhenwei Teo | ![]() |
![]() |
|||
749-P | NEW STRATEGIES OF ANALYSIS WITH FLOW CYTOMETRY FOR THE DIAGNOSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA | Paola Beneit | ![]() |
![]() |
|||
750-P | FREQUENT MUTATION OF THE MYD88 GENE IN MACROGLOBULINEMIA | Naoki Mori | ![]() |
![]() |
|||
751-P | THE ROLE OF FLT3-LIGAND IN THE PROGRESSION OF MULTIPLE MYELOMA; FLT3-LIGAND RELEASED FROM BONE MARROW STROMAL CELLS ACTIVATED PI3K/AKT PATHWAY AND WNT SIGNALING | Sung-Soo Yoon | ![]() |
![]() |
|||
752-P | CIRCULATING MICRORNA AS POTENTIAL BIOMARKERS OF MGUS AND MM | Lenka Kubiczkova | ![]() |
![]() |
|||
754-P | DEF124B, A MEMBER OF THE ?-DEFENSINS, IS DOWNREGULATED IN DIFFERENTIATING OSTEOBLASTS BY EXPOSURE TO IMIDS AND MAY MEDIATE THE SUPPRESSIVE EFFECT OF THESE AGENTS ON OSTEOGENESIS | Heinz Ludwig | ![]() |
![]() |
|||
755-P | IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 IN MYELOMA | Jacqueline Noll | ![]() |
![]() |
|||
757-P | NEUTROPHILS ARE IMPAIRED IN MULTIPLE MYELOMA BUT NOT IN MGUS | ALESSANDRA ROMANO | ![]() |
![]() |
|||
758-P | IDENTIFICATION OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 (IGFBP7) AS TUMOR SUPPRESSOR IN MULTIPLE MYELOMA LINKED TO THE PRESENCE OF OSTEOLYTIC LESIONS AND OVERALL SURVIVAL | Heinz Ludwig | ![]() |
![]() |
|||
759-P | HIGH RISK CYTOGENETIC ABNORMALITIES AND PLASMA CELLS PHENOTYPE INDUCE SIGNIFICANT ALTERATIONS IN BONE MARROW B-CELL COMPARTMENTS IN MONOCLONAL GAMMOPATHIES | Sofia Ramos | ![]() |
![]() |
|||
760-P | ANGIOPOIETIN-2 AND MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA HAVE DUAL EFFECT ON BONE INVOLVEMENT AND ANGIOGENESIS IN MULTIPLE MYELOMA | George Tsirakis | ![]() |
![]() |
|||
761-P | GENE EXPRESSION OF BONE MODULATORS IN WHOLE BONE MARROW BIOPSIES IN CORRELATION TO DYNAMIC BONE MARKERS IN MULTIPLE MYELOMA BONE DISEASE | Ida Bruun Kristensen | ![]() |
![]() |
|||
762-P | P15 AND DAPK METHYLATION IN MULTIPLE MYELOMA AND MGUS: COMPARISON BETWEEN BONE MARROW AND PERIPHERAL BLOOD | Catarina Geraldes | ![]() |
![]() |
|||
768-P | SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL | Paul Richardson | ![]() |
![]() |
|||
769-P | CONSOLIDATION WITH HD- MELPHALAN AND AUTOTRANSPLANT (ASCT) AFTER SECOND-LINE TREATMENT INCREASES RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN MYELOMA PATIENTS RELAPSED AFTER FIRST-LINE ASCT | Claudia Crippa | ![]() |
![]() |
|||
770-P | TOTAL THERAPY 3 (TT3)-BASED TREATMENT FOR MULTIPLE MYELOMA AN EXTENDED SINGLE CENTER EXPERIENCE | Eli muchtar | ![]() |
![]() |
|||
772-P | MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT | Jeffrey Matous | ![]() |
![]() |
|||
773-P | CAUSES OF DEATH 30 AND 180 DAYS AFTER DIAGNOSIS IN NON-HDT TREATED DANISH MULTIPLE MYELOMA PATIENTS: A STUDY FROM THE DANISH MYELOMA STUDY GROUP | Morten Orebo Holmstrm | ![]() |
![]() |
|||
774-P | PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) | Elizabeth Bilotti | ![]() |
![]() |
|||
777-P | THE UK LENALIDOMIDE TREATMENT CONTINUATION SCHEME: TRENDS OF LONG-TERM TREATMENT IN A CLINICAL SETTING | Cathy Williams | ![]() |
![]() |
|||
778-P | THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS | Sundar Jagannath | ![]() |
![]() |
|||
779-P | PROMISING ROLES OF AMIFOSTINE AS PROPHYLACTIC AGENTS AGAINST BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY | Meiyun Fang | ![]() |
![]() |
|||
780-P | MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS | Johan Lund | ![]() |
![]() |
|||
781-P | CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS | Katarina Uttervall | ![]() |
![]() |
|||
784-P | SESTAMIBI TECHNETIUM-99M BONE MARROW SCAN IS ABLE TO PREDICT OVERALL DISEASE OUTCOME AND MORTALITY COMPARED TO WHOLE BODY MAGNETIC RESONANCE IMAGING IN MULTIPLE MYELOMA | Alhossain Khalafallah | ![]() |
![]() |
|||
788-P | ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | Michel Delforge | ![]() |
![]() |
|||
789-P | VTD CONSOLIDATION, WITHOUT BISPHOSPHONATES, REDUCES BONE RESORPTION AND IS ASSOCIATED WITH A VERY LOW INCIDENCE OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA POST-ASCT | Dimitrios Christoulas | ![]() |
![]() |
|||
790-P | IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS | Michele Cavo | ![]() |
![]() |
|||
791-P | TREATMENT WITH BORTEZOMIB-BASED REGIMENS IMPROVES OVERALL RESPONSE AND PREDICTS FOR SURVIVAL IN PATIENTS WITH PRIMARY OR SECONDARY PLASMA CELL LEUKEMIA: ANALYSIS OF THE GREEK MYELOMA STUDY GROUP | Eirini Katodritou | ![]() |
![]() |
|||
792-P | EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED DATA ON SAFETY AND SPM INCIDENCE IN PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB | Michele Cavo | ![]() |
![]() |
|||
794-P | CIRCULATING SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (SRANKL) AND C-C MOTIF LIGAND-3 (CCL-3) LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA | Dimitrios Christoulas | ![]() |
![]() |
|||
795-P | RESULTS OF THE DUTCH COMMUNITY BASED TRIAL VALEO WITH BORTEZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS | Richard Milek | ![]() |
![]() |
|||
797-P | HIGH RISK CYTOGENETICS, ELEVATED LDH AND ISS-3 IDENTIFY A SUBGROUP OF MYELOMA PATIENTS WITH VERY POOR PROGNOSIS | Efstathios Kastritis | ![]() |
![]() |
|||
798-P | BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA | Kay Reen Ting | ![]() |
![]() |
|||
799-P | EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY | Belén Liébana | ![]() |
![]() |
|||
800-P | THE IMPACT OF 8 GY ONE FRACTION RADIOTHERAPY ON PAIN RELIEF AND RECALCIFICATION IN MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS. | Milda Rudzianskiene | ![]() |
![]() |
|||
801-P | RESULTS OF LENALIDOMIDE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN A REAL WORLD SETTING: FEASIBILITY AND FACTORS CONTRIBUTING TO LONG TREATMENT DURATION | Gunter Derigs | ![]() |
![]() |
|||
802-P | THE PRESENCE OF IMMUNOPHENOTYPIC ALTERATIONS IN BONE MARROW CELLS OTHER THAN PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS PREDICTS FOR MYELODYSPLASIA-ASSOCIATED CYTOGENETIC ABNORMALITIES | Sergio Matarraz | ![]() |
![]() |
|||
804-P | FLOW CYTOMETRIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A COMPARISON BETWEEN FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CYCLOSCOPE-MG. | GIACOMA DE TULLIO | ![]() |
![]() |
|||
805-P | NUMBER OF ADVERSE CYTOGENETIC LESIONS DETECTED BY FISH IS ASSOCIATED WITH PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-BASED REGIMENS | Norbert Grzasko | ![]() |
![]() |
|||
806-P | EVALUATION OF TNF SUPERFAMILY MOLECULES IN MULTIPLE MYELOMA PATIENTS: CORRELATION WITH BIOLOGICAL AND CLINICAL FEATURES. | Bolkun Lukasz | ![]() |
![]() |
|||
807-P | TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | Heinz Ludwig | ![]() |
![]() |
|||
808-P | VALUE OF WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN THE STUDY OF MONOCLONAL GAMMOPATHIES AND CORRELATION WITH BONE-RELATED CYTOKINES | RAFAEL MARTOS MARTINEZ | ![]() |
![]() |
|||
809-P | THE COMBINATION OF BORTEZOMIB AND DEXAMETHASONE (VD) ALONG WITH ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY (BMD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY | Dimitrios Christoulas | ![]() |
![]() |
|||
810-P | LONG TERM THERAPY WITH LENALIDOMIDE DOES NOT SIGNIFICANTLY AFFECT THE CELLULAR COMPOSITION OF THE BONE MARROW | Annamaria Brioli | ![]() |
![]() |
|||
811-P | A RETROSPECTIVE REVIEW OF THE INCIDENCE OF CONTRAST INDUCED NEPHROPATHY IN THE MYELOMA SETTING | Maeve Crowley | ![]() |
![]() |
|||
812-P | EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS | wenming chen | ![]() |
![]() |
|||
813-P | THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS | Jian Hou | ![]() |
![]() |
|||
816-P | LONG TERM FOLLOW-UP OF TREATMENT WITH IMATINIB IN EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS WITH PDGFR REARRANGEMENTS IN ADVANCED PHASE | Georgia Metzgeroth | ![]() |
![]() |
|||
819-P | HOW MANY CHILDREN WITH THROMBOCYTOSIS OF UNDEFINED ORIGIN HAVE A MYELOPROLIFERATIVE NEOPLASM? | Maria Luigia Randi | ![]() |
![]() |
|||
821-P | CLINICAL FEATURES OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPLICATED BY PORTAL HYPERTENSION | Matthew Yan | ![]() |
![]() |
|||
822-P | EOSINOPHILIA IN ROUTINE BLOOD SAMPLES AND THE SUBSEQUENT RISK OF HEMATOLOGICAL MALIGNANCIES AND DEATH | Christen Andersen | ![]() |
![]() |
|||
823-P | CHRONIC MYELOPROLIFERATIVE NEOPLASMS REVEAL INCREASED RISK OF OSTEOPOROTIC FRACTURES | Sarah Farmer | ![]() |
![]() |
|||
824-P | DETERMINANTS AND FREQUENCY OF THROMBOTIC AND BLEEDING COMPLICATIONS IN AN ITALIAN COHORT OF 88 PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN): THE ROLE OF ADAMTS-13 AND VWF ACTIVITIES | Augusto B Federici | ![]() |
![]() |
|||
825-P | INTERNATIONAL PROGNOSTIC SCORE FOR ESSENTIAL THROMBOCYTHEMIA (IPSET) AND IPSET-THROMBOSIS ONE CENTRE ANALYSIS | TERESA GARRIDO | ![]() |
![]() |
|||
826-P | BCR/ABL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS | Laura Kesaeva | ![]() |
![]() |
|||
827-P | A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF) | Jessica Litvan | ![]() |
![]() |
|||
829-P | ADDITION OF THE DEGREE OF BONE MARROW FIBROSIS TO IPSS IN NEW SCORING SYSTEM IMPROVES PREDICTION OF SURVIVAL IN PRIMARY MYELOFIBROSIS | Danijela Lekovic | ![]() |
![]() |
|||
830-P | CONTRIBUTION OF SNP ARRAYS TO THE DIAGNOSIS AND PROGNOSIS OF CMML. A STUDY OF PATIENTS WITH LOW RISK CYTOGENETIC FEATURES AND CASES WITH ABSENCE OF METAPHASES | Laura Palomo | ![]() |
![]() |
|||
832-P | HIGHLY SPECIFIC QPCR ASSAYS USING CONSENSUS LNA PROBE FOR THE DETECTION OF t(11;14) AND t(14;18) IN NON-HODGKIN LYMPHOMA WITH A SENSITIVITY OF 10-5 FOR QUANTIFICATION OF MINIMAL RESIDUAL DISEASE | Camilla Darum Srensen | ![]() |
![]() |
|||
834-P | NR4A1 MEDIATED APOPTOSIS SUPPRESSES LYMPHOMAGENESIS IN A XENOGRAFT MOUSE MODEL | Alexander Deutsch | ![]() |
![]() |
|||
835-P | EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) | Mar Garcia | ![]() |
![]() |
|||
836-P | DLBCL BIOLUMINESCENT XENOGRAFT MODEL FOR NON-INVASIVE FOLLOW-UP OF ANTITUMOR EFFECT | María José Moreno Jiménez | ![]() |
![]() |
|||
837-P | BLOOD AND LYMPHATIC MICROENVIRONMENT, MACROPHAGE COMPONENT AS PROGNOSTIC MARKERS IN FOLLICULAR LYMPHOMA | Ekaterina Nesterova | ![]() |
![]() |
|||
841-P | IDENTIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) SUBTYPES DEFINED BY THE EXPRESSION OF STROMAL PROTEINS AND THEIR ASSOCIATION WITH MICRORNAS INVOLVED IN ANGIOGENESIS | Natália Borges | ![]() |
![]() |
|||
842-P | DISTINCT GENE EXPRESSION PROFILES IN A CANINE MODEL OF HUMAN DLBCL | Geertruy te Kronnie | ![]() |
![]() |
|||
844-P | CLINICAL SYMPTOM OR SIGN-DIRECTED SURVEILLANCE CAN BE MORE USEFUL TO DETECT RELAPSE COMPARED TO ROUTINE IMAGING IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AFTER COMPLETE REMISSION | Junshik Hong | ![]() |
![]() |
|||
845-P | VIROLOGICAL SUCCESS IS ASSOCIATED WITH FAVORABLE PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS. | Jean Marie Michot | ![]() |
![]() |
|||
847-P | HIGH-DOSE METHOTREXATE, HIGH-DOSE CYTARABINE AND TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA | maher salamoon | ![]() |
![]() |
|||
850-P | LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IS PROMISING: LONG TERM RESULTS OF THE PHASE II REAL07 STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL) | Annalisa Chiappella | ![]() |
![]() |
|||
851-P | PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL) | Pam Milner | ![]() |
![]() |
|||
852-P | PROSPECTIVE COHORT STUDY FOR SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CHOP | Seok Jin Kim | ![]() |
![]() |
|||
853-P | INTERIM PET-CT SCAN AFTER 2 CYCLES SUCCESSFULLY PREDICTS OUTCOME IN DLBL BUT INTRODUCES SIGNIFICANT SELECTION BIAS. | Nicholas Grigoropoulos | ![]() |
![]() |
|||
854-P | STAGING NEWLY DIAGNOSED LYMPHOMAS: COMPARISON BETWEEN WHOLE BODY-MRI/DWIBS AND 18FDG-PET/CT | Carla Minoia | ![]() |
![]() |
|||
855-P | CENTRAL NERVOUS SYSTEM RELAPSE IN NON HODGKIN LYMPHOMA: PROGNOSTIC FACTORS AND OUTCOME IN A COHORT OF 304 PATIENTS | Juanjosé Alonso | ![]() |
![]() |
|||
856-P | LYMPHOCYTE COUNT AT DIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE ERA OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB: IS 1000/MM3 STILL THE BEST CUT-OFF VALUE TO USE TO DEFINE LYMPHOPENIA ? | Alessia Bari | ![]() |
![]() |
|||
859-P | PROGNOSTIC FACTORS IN VERY OLD PATIENTS (= 75 YEARS) WITH FOLLICULAR LYMPHOMA: A MULTICENTRE RETROSPECTIVE STUDY | Anne Parcelier | ![]() |
![]() |
|||
860-P | EFFICACY AND SAFETY OF LENALIDOMIDE WITH/WITHOUT RITUXIMAB OR STEROIDS IN HEAVILY PRETREATED NON-HODGKINS B-CELL LYMPHOMAS: RESULTS OF A RETROSPECTIVE STUDY | ANNALISA CHIAPPELLA | ![]() |
![]() |
|||
862-P | SERUM FREE LIGHT CHAINS LEVELS IN PATIENTS WITH HIV-RELATED LYMPHOMA ARE LOWER AT COMPLETE RESPONSE THAN AT DIAGNOSIS | Maria Joao Baptista | ![]() |
![]() |
|||
863-P | PROGNOSTIC RELEVANCE OF FDG-PET IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA | Gayane Tumyan | ![]() |
![]() |
|||
864-P | FC-GAMMA-RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE DO NOT INFLUENCE TREATMENT OUTCOMES AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP PROTOCOL | Laszlo Varoczy | ![]() |
![]() |
|||
865-P | INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR RESISTANT FOLLICULAR NON HODGKIN LYMPHOMA: RESULTS FROM AN EXPLORATORY GITIL STUDY | Caterina Patti | ![]() |
![]() |
|||
866-P | THE INTENSITY AND DURATION OF PAIN ASSOCIATED WITH TREPHINE BIOPSY | Waleed Ghanima | ![]() |
![]() |
|||
869-P | THE ROLEOF PET/CT FOR EVOLUATION OF THE BONE MARROW INVOLVEMENT IN LYMPHOMA PATIENTS | asu fergun yilmaz | ![]() |
![]() |
|||
870-P | ANALYSIS OF THE BONE MARROW INFILTRATION IN A GROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA BY COMPARING BONE MARROW BIOPSY AND 18F-FDG PET/CT | Paula César | ![]() |
![]() |
|||
871-P | COMPARISONS OF B-CELL AND T-CELL LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | Jui-Ting Yu | ![]() |
![]() |
|||
873-P | HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION | Eisei Kondo | ![]() |
![]() |
|||
874-P | A MULTICENTRE REVIEW OF THE OUTCOMES OF PATIENTS ABOVE THE AGE OF 75 WITH PRIMARY DIFFUSE LARGE B CELL LYMPHOMA | Vikramajit Singh | ![]() |
![]() |
|||
875-P | HUMAN CORD BLOOD CD45 CELLS PROTECT MICE BRAIN AFTER CLOSED HEAD INJURY | Hadar Arien-Zakay | ![]() |
![]() |
|||
876-P | PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY | Federica Cattina | ![]() |
![]() |
|||
878-P | DIFFERENT DOSE OF ATG INDUCTION THERAPY IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: LONG TERM EFFECT ON TH17 AND CONVENTIONAL T CELLS, NOT ON NK RESPONSES | Xiang-Yu Zhao | ![]() |
![]() |
|||
879-P | CIRCULATING ENDOTHELIAL CELLS (CEC) ARE A RELIABLE AND DYNAMIC BIOMARKER OF ACUTE GVHD (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION. | Andrea Di Palma | ![]() |
![]() |
|||
880-P | EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION ON THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS | Qifa Liu | ![]() |
![]() |
|||
883-P | PARALEL STUDY OF CHIMERISM AFTER ALLOGENIC HAEMTOPOIETIC STEM CELL TRANSPLANTATION MONITORED BY TWO DIFFERENT MOLECULAR METHODS | Eva Hanusovska | ![]() |
![]() |
|||
884-P | VENO-OCCLUSIVE DISEASE MAY DEVELOP IN SECONDARY IRON OVERLOADED MICE AFTER TOTAL BODY IRRADIATION. | Dae Chul Jeong | ![]() |
![]() |
|||
887-P | STUDY OF SOLUBLE HLA-G LEVEL DYNAMICS IN HEMATOLOGICAL PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION | Elena Ribakovsky | ![]() |
![]() |
|||
889-P | CONTROLLED EPSTEIN-BARR VIRUS REACTIVATION AFTER ALLOGENIC TRANSPLANTATION IS ASSOCIATED WITH IMPROVED SURVIVAL ASSOCIATED TO AN EXPANSION OF NATURAL KILLER CELLS (NK). | JEAN FRANCOIS ROSSI | ![]() |
![]() |
|||
890-P | MYELOABLATIVE FLUDARABINE PLUS BUSULFAN IV (FB4) REGIMEN COMPARES FAVOURABLY WITH CYCLOPHOSPHAMIDE PLUS BUSULFAN (BUCY) IN PATIENTS UNDERGOING ALLO-SCT FOR MYELOID MALIGNANCY | Valerie COITEUX | ![]() |
![]() |
|||
891-P | LONG-TERM OUTCOME (BEYOND 10 YEARS) AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION WITH REDUCED-INTENSITY COMPARED TO MYELOABLATIVE CONDITIONING; SIMILAR SURVIVAL BUT DIFFERENT PATTERN OF LATE EVENTS | Avichai Shimoni | ![]() |
![]() |
|||
892-P | HOW MANY AML PATIENTS DO RECEIVE EARLY ALLOGENEIC BONE MARROW TRANSPLANT AND WHICH TRANSPLANT IS PERFORMED? REAL LIFE DATA FROM GENOVA ACUTE LEUKEMIA REGISTRY (REGAL). | Marino Clavio | ![]() |
![]() |
|||
893-P | THE MANAGEMENTS OF EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
894-P | ASSOCIATION OF HLA POLYMORPHISMS WITH EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
895-P | PERFORMANCE OF FECAL CALPROTECTIN FOR THE DIAGNOSIS AND FOLLOW UP OF ACUTE GASTRO-INTESTINAL GRAFT VERSUS HOST DISEASE | Marta Lisa Battista | ![]() |
![]() |
|||
896-P | IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA | Luisa Giaccone | ![]() |
![]() |
|||
898-P | THREE DAYS BUSULFAN ASSOCIATED WITH FLUDARABINE AND ANTITHYMOGLOBULINE CONDITIONING: IS IT SAFE? | Sylvain Chantepie | ![]() |
![]() |
|||
899-P | IMPROVED OUTCOME WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A POOR PROGNOSTIC SUBGROUP OF PATIENTS WITH MIXED-LINEAGE-LEUKEMIAREARRANGED LEUKEMIA: RESULTS FROM A SINGLE-CENTER PROSPECTIVE STUDY | yu wang wang | ![]() |
![]() |
|||
902-P | MOBILIZATION AND ENGRAFTMENT OF PERIPHERAL BLOOD STEM CELLS IN RELATED HEALTHY DONORS OLDER THAN 55 YEARS | Cristina Motlló | ![]() |
![]() |
|||
903-P | EFFICACY OF ORAL BUDESONIDE FOR GASTROINTESTINAL GRAFT VERSUS HOST DISEASE IN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | Mui Fong Chong | ![]() |
![]() |
|||
905-P | MYELOABLATIVE CONDITIONING REGIMEN WITHOUT ATG AND TBI IN SINGLE UNIT UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH HEMATOLOGIC MALIGNANCIES | Juan Tong | ![]() |
![]() |
|||
907-P | IMPACT OF INAPPROPRIATE MICAFUNGIN PROPHYLAXIS IN A BONE MARROW TRANSPLANTATION (BMT) UNIT ON THE OUTCOME OF CANDIDIASIS AND ON THE EMERGENCE OF ECHINOCANDIN-RESISTANT CANDIDA KRUSEI ISOLATES | Emmanuelle Tavernier | ![]() |
![]() |
|||
909-P | SIMILAR OUTCOMES BETWEEN YOUNGER AND OLDER AGE GROUP IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO RECEIVED HLA-MATCHED SIBLING TRANSPLANTS WITH FLUDARABINE-BASED CONDITIONING | Seung Hwan Shin | ![]() |
![]() |
|||
910-P | POORER OUTCOME AFTER CORD BLOOD THAN AFTER MATCHED RELATED OR UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION PREPARED WITH REDUCED TOXICITY CONDITIONING FOR HIGH RISK ACUTE MYELOID LEUKEMIA | devillier raynier | ![]() |
![]() |
|||
912-P | KIR-LIGAND INCOMPATIBILITY IN THE GRAFT-VERSUS-HOST DIRECTION DID NOT AFFECT OUTCOMES OF SINGLE UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT ATG FOR ACUTE LEUKEMIA IN COMPLETE REMISSION | Junji Tanaka | ![]() |
![]() |
|||
914-P | PROGNOSTIC IMPACT OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS WITH MYELOID NEOPLASMS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION A SINGLE INSTITUTION SERIES | Desire Gijima | ![]() |
![]() |
|||
915-P | IN VIVO T-CELL DEPLETION WITH LOW-DOSE ANTITHYMOCYTE GLOBULIN TO REDUCE ACUTE GVHD IN UNRELATED DONOR STEM CELL TRANSPLANT FOR PATIENTS WITH SEVERE APLASTIC ANEMIA | Sung-Eun Lee | ![]() |
![]() |
|||
916-P | IMPACT OF ABO INCOMPATIBILITY ON UNRELATED CORD BLOOD TRANSPLANTATION | Yao Wen | ![]() |
![]() |
|||
917-P | SECONDARY ANTIFUNGAL PROPHYLAXIS BASED ON RESPONSE TO INITIAL ANTIFUNGAL THERAPY FOR PATIENTS WITH A HISTORY OF INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | ![]() |
![]() |
|||
918-P | A MONOCLONAL PROTEIN FOUND IN RELATED STEM CELL DONORS: ARE WE DOING IT RIGHT? | Nicolette Tiren-Verbeet | ![]() |
![]() |
|||
919-P | TBI AND CYCLOPHOSPHAMIDE PLUS ATG IS WELL TOLERATED AND EFFECTIVE AS A PREPARATIVE REGIMEN FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION | Haixia Fu | ![]() |
![]() |
|||
920-P | HIGH LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR IS ASSOCIATED WITH INCREASED RELAPSE RATE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Ivan Moiseev | ![]() |
![]() |
|||
921-P | CLINICAL IMPACT OF ENGRAFTMENT SYNDROME IN ADULT PATIENTS WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION | Hiroaki Shimizu | ![]() |
![]() |
|||
924-P | THERAPEUTIC APPROACH TO RELAPSE OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Claudia Moreira | ![]() |
![]() |
|||
925-P | IMPACT OF THE 2009 UK UMBILICAL CORD BLOOD TRANSPLANT CONSENSUS STATEMENT ON PRACTICE AND OUTCOMES AT A SINGLE TRANSPLANT CENTRE | chloe anthias | ![]() |
![]() |
|||
926-P | CMV-SPECIFIC CD8 T-CELL IMMUNE RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION MONITORED BY HLA-MULTIMERS | EDUARDO OLAVARRIA | ![]() |
![]() |
|||
927-P | IDENTIFICATION OF THE EARLIEST BRANCH POINT FOR MYELO-ERYTHROID DEVELOPMENT IN ADULT HEMATOPOIESIS | Kohta Miyawaki | ![]() |
![]() |
|||
932-P | Studies of JARID1B in Hematopoiesis Using Gene Knockdown and Overexpression Assay | Jingxuan Zhang | ![]() |
![]() |
|||
933-P | ROLE OF BMI-1 IN NORMAL MOUSE HEMATOPOIETIC STEM CELLS AND LEUKEMIC CELLS | Yuk Man Lam | ![]() |
![]() |
|||
934-P | CONNECTIVE TISSUE GROWTH FACTOR (CTGF) CONFERS CELL ADHESION-MEDIATED DRUG-RESISTANCE (CAM-DR) IN ACUTE MYELOID LEUKEMIA | Saskia Pante | ![]() |
![]() |
|||
935-P | HUMAN BONE MARROW ADIPOCYTES MAINTAIN THE SURVIVAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS | Giulia Maurizi | ![]() |
![]() |
|||
937-P | ANALYSIS OF HUMAN ENDOSTEAL HSC NICHE; A NOVEL POPULATION WITH HIGH EXPRESSION OF CD34 AND ESAM IS ADJACENT TO TRABECULAR AREAS OF HUMAN BONE MARROW | MICHIKO ICHII | ![]() |
![]() |
|||
938-P | HEAD-TO-HEAD COMPARATIVE STUDY OF WHARTONS JELLY AND BONE MARROW MESENCHYMAL STEM CELLS | Charalampos Pontikoglou | ![]() |
![]() |
|||
939-P | ALTERATION IN GENE EXPRESSION PATTERN IN STROMAL PRECURSOR CELLS OF PATIENTS BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION | Irina Shipounova | ![]() |
![]() |
|||
940-P | ROLE OF BONE MARROW STROMAL CELLS IN THE REGULATION OF HUMAN EARLY LYMPHOPOIESIS | Kohshi Ohishi | ![]() |
![]() |
|||
941-P | DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA | Francesco Dalň | ![]() |
![]() |
|||
943-P | UMBILICAL CORD MESENCHYMAL STEM CELLS WITH IMPROVED SUPPORT FOR HEMATOPOIETIC STEM CELL EXPANSION. | Pavel Butylin | ![]() |
![]() |
|||
944-P | ENDOTHELIAL CELLS EXPRESSING CONSTITUTIVELY ACTIVE AKT1 ARE CAPABLE OF RECONSTITUTING OF VASCULAR NICHE IN VITRO. | Pavel Butylin | ![]() |
![]() |
|||
945-P | CHEMOKINE SIGNALLING REGULATES HAEMOPOIETIC STEM CELL PROPERTIES | Amy Sinclair | ![]() |
![]() |
|||
947-P | MONOALLILIC MUTATIONS OF FHL-RELATED GENES PREDISPOSE TO MACROPHAGE ACTIVATION SYNDROME | Elena Sieni | ![]() |
![]() |
|||
949-P | COMBINED APPLICATION OF MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION AND FLUORESCENCE IN SITU HYBRIDIZATION TO DETECT CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA | Donat Alpar | ![]() |
![]() |
|||
950-P | COMPARISON OF MICROARRAY-BASED GENOMIC PROFILING AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) FOR THE DETECTION OF CLINICALLY RELEVANT GENETIC LESIONS, INCLUDING IKZF1, IN ALL | Marian Stevens-Kroef | ![]() |
![]() |
|||
955-P | ARRAY-BASED GENOMIC PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IDENTIFIES HIGHER NUMBER OF PROGNOSTIC RELEVANT GENOMIC ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES | Marian Stevens-Kroef | ![]() |
![]() |
|||
956-P | DEREGULATION OF STEM CELL FACTOR (SCF)-AKT-S6 PATHWAY IN DIAGNOSTIC AML SAMPLES IS ASSOCIATED WITH DISEASE-FREE SURVIVAL: RESULTS OF A VERIFICATION STUDY | Michelle Atallah | ![]() |
![]() |
|||
957-P | HIGH-RESOLUTION GENOMIC PROFILING IN MULTIPLE MYELOMA IDENTIFIES RECURRENT PROGNOSTIC RELEVANT COPY NUMBER ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES | Marian Stevens-Kroef | ![]() |
![]() |
|||
959-P | IMPORTANCE OF MICROARRAY ANALYSIS AS A PROGNOSTIC CLINICAL TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA | Nolwen Prie | ![]() |
![]() |
|||
961-P | CHARACTERISTICS OF VARIANT AND ADDITIONAL CYTOGENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES | Eunhae Cho | ![]() |
![]() |
|||
962-P | MUTATIONAL STUDY OF DNMT3A IN ACUTE MYELOID LEUKEMIA | Seung Hwan Oh | ![]() |
![]() |
|||
965-P | EX VIVO SENSITIVITY AND RESISTANCE MECHANISMS TO CLOFARABINE IN CHILDHOOD ACUTE LEUKEMIA | Baleydier Frederic | ![]() |
![]() |
|||
967-P | TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS | Athina Giannoudis | ![]() |
![]() |
|||
968-P | TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML | Daniel Sasca | ![]() |
![]() |
|||
969-P | TRANSCRIPTIONAL PROGRAMMES ASSOCIATED WITH EVI1 MEDIATED CHEMOTHERAPY RESISTANCE OF HUMAN MYELOID CELLS | Rotraud Wieser | ![]() |
![]() |
|||
970-P | KNOCKDOWN OF NUCLEOPHOSMIN BY RNA INTERFERENCE REVERSES MULTIDRUG RESISTANCE IN RESISTANT LEUKEMIC HL-60 CELLS | Jianda Hu | ![]() |
![]() |
|||
972-P | POLYMORPHISMS OF MULTIDRUG RESISTANCE TRANSPORTER (ABCG2 AND ABCB1) GENES IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA | Hajnalka Andrikovics | ![]() |
![]() |
|||
976-P | EVIDENCE THAT THE PREGNANE X AND RETINOID RECEPTORS PXR, RAR AND RXR MAY REGULATE TRANSCRIPTION OF THE IMATINIB TRANSPORTER HOCT1 EXPRESSION IN CHRONIC MYELOID LEUKAEMIA CELLS | Lihui Wang | ![]() |
![]() |
|||
977-P | THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM | Ibrahim El-Serafi | ![]() |
![]() |
|||
978-P | ABCB1 HAPLOTYPE IS ASSOCIATED WITH ALTERATIONS IN FUNCTIONAL ACTIVITY OF P-GP AND AFFECTS MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD-DOSE OF IMATINIB | Douglas Vivona | ![]() |
![]() |
|||
979-P | DIAGNOSTIC AND THERAPEUTIC POTENTIALS OF EXPRESSION LEVELS OF BIOACTIVE SPHINGOLIPID GENES IN NEWLY DIAGNOSED AND DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS | Yusuf Baran | ![]() |
![]() |
|||
980-P | SMO INHIBITOR SPECIFICALLY TARGETS THE HEDGEHOG PATHWAY AND REVERTS THE DRUG-RESISTANCE OF LEUKEMIC STEM CELLS | viviana guadagnuolo | ![]() |
![]() |
|||
983-P | CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA | Kristin MacIntosh | ![]() |
![]() |
|||
987-P | PULMONARY EFFECTS OF PERFLUOROCARBON EMULSION THERAPY ON INFECTED SICKLE CELL MICE | Nawal Helmi | ![]() |
![]() |
|||
988-P | THE BTK-SPECIFIC INHIBITOR ONO-4059 SYNERGIZES WITH THE BCL2 INHIBITOR ABT-263. | Martin Dyer | ![]() |
![]() |
|||
989-P | EFFICIENCY OF CD19 TARGETING BY MONOCLONAL ANTIBODIES IN EX VIVO AND MOUSE MODELS OF CHILDREN ACUTE B-LYMPHOBLASTIC LEUKEMIAS | Arthur Dony | ![]() |
![]() |
|||
990-P | INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20 EXPRESSION AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES | Malgorzata Wanczyk | ![]() |
![]() |
|||
991-P | BOTANICAL ALKYL HYDROQUINONE HQ17(3) EXHIBITS CYTOTOXIC EFFECT ON SUP-B15 ALL CELLS HARBORING T(9;22) PHILADELPHIA CHROMOSOME THROUGH INDUCING IRON-DEPENDENT LYSOSOMAL EVENTS AND OXIDATIVE STRESS | Chung-Yi Hu | ![]() |
![]() |
|||
995-P | THE DONOR DEPENDENT IMMUNE MODULATORY POTENTIAL OF MESENCHYMAL STROML CELL PREPARATIONS CAN BE PREDICTED BY GALECTIN-9 | Christopher Ungerer | ![]() |
![]() |
|||
996-P | INCREASING SAFETY AND EFFICACY OF TCR TRANSFER BY EMPLOYING A MINIMALLY MURINIZED HUMAN TUMOR-REACTIVE SINGLE-CHAIN TCR | Beate Hauptrock | ![]() |
![]() |
|||
998-P | STAINING OF ANTIGEN-SPECIFIC CD4 T CELLS USING MHC CLASS II TETRAMERS GENERATED ACCORDING TO A NOVEL METHOD OF PEPTIDE-MHC CLASS II MONOMER PRODUCTION AND PURIFICATION | Peter Braendstrup | ![]() |
![]() |
|||
999-P | PMHC ARRAYS DEMONSTRATE THAT UNTOUCHED T CELL POPULATIONS FROM PRESENTATION ACUTE MYELOID LEUKAEMIA PATIENTS PREDOMINANTLY RECOGNIZE THE CANCER-TESTIS ANTIGEN, PASD1 | Barbara Guinn | ![]() |
![]() |
|||
1000-P | CYTOKINE INDUCED KILLER CELLS ARE ACTIVE AGAINST NON-SMALL CELL LUNG CANCER AND OVERCOME THE ACQUIRED RESISTANCE TO TARGET THERAPIES | Maja Todorovic | ![]() |
![]() |
|||
1002-P | NATURAL KILLER CELL EXPANSION UNDER GOOD MANUFACTURING PRACTICE CONDITIONS FOR CLINICAL USE IN ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Nadia Peragine | ![]() |
![]() |
|||
1003-P | EFFICIENT GENERATION OF HLA-A2 AND A24-RESTRICTED WT1-SPECIFIC CYTOTOXIC T LYMPHOCYTES USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS | Masahiro Ogasawara | ![]() |
![]() |
|||
1004-P | OPTIMIZATION OF ALLOGENEIC NK CELLS FOR ADOPTIVE TRANSFER THERAPY | Michal Besser | ![]() |
![]() |
|||
1007-P | CENTRALIZED PRODUCTION AND DISTRIBUTION OF CMV-SPECIFIC CYTOTOXIC T CELL LYMPHOCYTES | Anke Friedetzky | ![]() |
![]() |
|||
1008-P | LAK CELLS AND ANTI-CD20 MONOCLONAL ANTIBODIES AS INMUNOTHERAPY ON FOLLICULAR LYMPHOMA: ENCHANCED ANTIBODY-DEPENDENT CELL CITOTOXICITY OF LAK CELLS IN ASSOCIATION WITH GA101 RATHER THAN RITUXIMAB | Alfonso Piérola Ana | ![]() |
![]() |
|||
1009-P | ROLE OF CIRCULATING &945;&946;-DOUBLE NEGATIVE T CELLS (DNT) IN LYMPHOMA PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY | Giacoma De Tullio | ![]() |
![]() |
|||
1010-P | EFFECT OF HISTONE METHYLTRANSFERASE EZH2 INHIBITOR 3-DEAZANEPLANOCIN A (DZNEP) ON ERYTHROPOIESIS | Tohru Fujiwara | ![]() |
![]() |
|||
1011-P | Locus Control Region in the HBB globin cluster: HS3 deletion has a very limited effect over adult globin gene expression | Felix De La Fuente | ![]() |
![]() |
|||
1013-P | INHIBITION OF ERYTHROPOIESIS THROUGH HEPCIDIN AND ROS IN TRANSFUSION-RELATED IRON OVERLOAD MICE | MASAYOSHI MASUKO | ![]() |
![]() |
|||
1014-P | CONGENITAL DYSERYTHROPOIETIC ANEMIA DUE TO A NOVEL GATA-1 MUTATION | Janet Pereira | ![]() |
![]() |
|||
1015-P | EFFECTS OF CHRONIC PSYCHOLOGICAL STRESS ON EXTRAMEDULLARY ERYTHROPOIESIS: INVOLVEMENT OF EPOR, GR, C-KIT AND BMP4 SIGNALING | Mirela Budec | ![]() |
![]() |
|||
1016-P | DOES THE OPTICAL MICROSCOPE TELL US THE COMPLETE STORY IN MEMBRANE-CYTOSKELETON DISORDERS? A STUDY OF RED BLOOD CELLS WITH ATOMIC-FORCE AND SCANNING-ELECTRON MICROSCOPES IN HEREDITARY SPHEROCYTOSIS | Dimosthenis Stamopoulos | ![]() |
![]() |
|||
1017-P | INVESTIGATION OF HEMORHEOLOGICAL PARAMETERS AT THE DIAGNOSIS AND THE FOLLOW-UP OF NUTRITIONAL VITAMIN B12 DEFICIENT CHILDREN | Hazal Tancer-Eli | ![]() |
![]() |
|||
1018-P | X-LINKED SIDEROBLASTIC ANEMIA: A PROMOTER MUTATION IN THE ALAS2 GENE | Janet Pereira | ![]() |
![]() |
|||
1022-P | IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES | Afsaneh Abdolzade-Bavil | ![]() |
![]() |
|||
1024-P | LIPEGFILGRASTIM A LONG-ACTING, ONCE-PER-CYCLE, GLYCOPEGYLATED RECOMBINANT HUMAN FILGRASTIM CREATED WITH SITE-SPECIFIC GLYCOPEGYLATION TECHNOLOGY | Christian Scheckermann | ![]() |
![]() |
|||
1025-P | SAFETY AND TOLERABILITY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN INTEGRATED ANALYSIS OF PHASE II AND III STUDIES | Oleg Gladkov | ![]() |
![]() |
|||
1026-P | CARDIAC INVOLVEMENT IN TYPE 3 EGYPTIAN GAUCHER DISEASE PATIENTS: A REPORT OF 7 CASES AND A NEWLY REPORTED ANOMALY | Magy Abdelwahab | ![]() |
![]() |
|||
1027-P | A FEASIBILITY STUDY OF HOME MONITORING OF BLOOD NEUTROPHIL COUNTS IN PATIENTS WITH CHRONIC NEUTROPENIA | David Dale | ![]() |
![]() |
|||
1029-P | LANGERHANS CELL HISTEOCYTOSIS (LCH) IN EGYPTIAN CHILDREN. A SINGLE CENTER EXPERIENCE. | Sedky Mohamed Sedky | ![]() |
![]() |
|||
1030-P | PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA | Claudio Cerchione | ![]() |
![]() |
|||
1031-P | CHRONIC BENIGN NEUTROPENIA IN ADULTS: LABORATORY AND CLINICAL PARAMETERS OF A 6-YEAR FOLLOW-UP | BRUNO FATTIZZO | ![]() |
![]() |
|||
1034-P | LANGERHANS CELL HISTIOCYTOSIS: ONE CENTER EXPERIENCE BETWEEN 1990-2012 | Tulin Tiraje Celkan | ![]() |
![]() |
|||
1035-P | A NEW TYPE OF CHEDIAK-HIGASHI SYNDROME? CASE REPORT OF A BLACK HAIRED GIRL WITHOUT OCULOCUTANEUS ALBINISM PRESENTED WITH EARLY ONSET HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | Halil Ugur Hatipoglu | ![]() |
![]() |
|||
1036-P | CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY | Oleg Gladkov | ![]() |
![]() |
|||
1037-P | USE OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (CITP) DURING PERI-OPERATIVE PERIOD | William Alexander | ![]() |
![]() |
|||
1039-P | A MULTICENTER OBSERVATIONAL STUDY FOR EARLY DIAGNOSIS OF GAUCHER DISEASE IN PATIENTS WITH SPLENOMEGALY AND/OR THROMBOCYTOPENIA | Irene Motta | ![]() |
![]() |
|||
1040-P | A RETROSPECTIVE ANALYSIS OF EPSILON-AMINO-CAPROIC ACID THERAPY IN HYPOPROLIFERATIVE THROMBCYTOPENIA | Shweta Jain | ![]() |
![]() |
|||
1041-P | THE USE OF MYCOPHENOLATE MOFETIL IN THE TREATMENT OF CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA PURPURA | Alice Taylor | ![]() |
![]() |
|||
1043-P | DURATION OF BLEEDING SYMPTOMS 14 DAYS BEFORE DIAGNOSIS IS A STRONG PREDICTOR FOR DEVELOPMENT OF CHRONICITY IN CHILDHOOD PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) | Andromachi Papagianni | ![]() |
![]() |
|||
1044-P | PLATELET ACTIVATION MARKERS IN PATIENTS WITH INCREASED CARDIOVASCULAR RISK | Gavriilaki Eleni | ![]() |
![]() |
|||
1046-P | THROMBOCYTOPENIA PREDICT MORTALITY IN CRITICALLY ILL PATIENTS | Emel Gurkan | ![]() |
![]() |
|||
1049-P | THE IMMATURE PLATELET FRACTION IS SENSITIVE TO THE PLATELET SIZE AND A USEFUL PARAMETER FOR SCREENING FOR MACROTHROMBOCYTOPENIA | Miyazaki Koji | ![]() |
![]() |
|||
1052-P | OVERVIEW OF RUSSIAN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) REGISTRY | Igor Lisukov | ![]() |
![]() |
|||
1053-P | DIFFERENTIAL DIAGNOSIS OF THROMBOTIC MICROANGIOPATHY: DATA FROM PADOVA TTP CASE SERIES | Giulia Berti de Marinis | ![]() |
![]() |
|||
1055-P | EXTREME THROMBOCYTOSIS ( 1000 X 109 /L) IN 336 PATIENTS- REPORT OF A FOUR-YEAR EXPERIENCE | Emmanouil Papadakis | ![]() |
![]() |
|||
1056-P | ANTIPLASMIN, BUT NOT AMILORIDE, PREVENTS SYNOVITIS AND CARTILAGE DESTRUCTION FOLLOWING HEMARTHROSIS IN HEMOPHILIC MICE | laurens nieuwenhuizen | ![]() |
![]() |
|||
1058-P | MOLECULAR DIAGNOSTIC IN 47 UNRELATED FAMILIES WITH HAEMOPHILIA A IN ARAGON (SPAIN) | Silvia Santa Catalina | ![]() |
![]() |
|||
1059-P | IMPAIRED PROPLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA | Koji Miyazaki | ![]() |
![]() |
|||
1060-P | MUTATION ANALYSIS IN TURKISH RARE BLOOD DISORDERS | D&304;DEM TORUN | ![]() |
![]() |
|||
1062-P | HOW DO WE ENCOUNTER RARE FACTOR DEFICIENCIES IN CHILDREN? SINGLE CENTER RESULTS | Zafer Salcioglu | ![]() |
![]() |
|||
1066-P | ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY: CLINICAL CHARACTERIZATION AND RECOVERY TO INFUSION OF VWF-CONTAINING CONCENTRATES | Chiara Ambaglio | ![]() |
![]() |
|||
1067-P | VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN HOSPITALIZED OBSTETRIC PATIENTS : A MULTICENTRE CROSS-SECTIONAL STUDY | Maeve Crowley | ![]() |
![]() |
|||
1068-P | INVESTIGATION TO IMPROVE DETECTION OF LUPUS ANTICOAGULANT IN A LOCAL POPULATION EXPERIENCING RECURRENT MISCARRIAGE AND INTRAUTERINE DEATH | Ailin McMahon | ![]() |
![]() |
|||
1070-P | THROMBOSIS IN CHILDHOOD ACUTE LEUKEMIA | yaman yntem | ![]() |
![]() |
|||
1072-P | ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL | Ibrahim Haznedaroglu | ![]() |
![]() |
|||
1073-P | MORTALITY OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO COAGULATION AND INFLAMMATORY BIOMARKERS | Shereef Elmoamly | ![]() |
![]() |
|||
1074-P | EPCR SER219GLY POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA | Sergey Kapustin | ![]() |
![]() |
|||
1075-P | POLYMORPHISM OF VASCULAR TONE REGULATING GENES AND THE RISK OF VENOUS THROMBOEMBOLISM IN INDIVIDUALS WITH INHERITED THROMBOPHILIA | Anastasia Polyakova | ![]() |
![]() |
|||
1076-P | PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA A SYSTEMATIC REVIEW | Mandy Lauw | ![]() |
![]() |
|||
1077-P | THROMBOPHILIAS INCIDENCE IN PATIENTS WITH FETAL LOSS IN LAST TRIMESTER AND EVALUATION OF THE EFFECTIVENESS OF TREATMENT | LAURA BERMEJO MARTÍNEZ | ![]() |
![]() |
|||
1079-P | THE NOVEL NOX INHIBITOR 2-ACETYLPHENOTHIAZINE IMPAIRS COLLAGEN-DEPENDENT THROMBUS FORMATION IN A GPVI-DEPENDENT MANNER | Dina Vara | ![]() |
![]() |
|||
1080-P | COMPARISON OF PATIENTS AND PHYSICIANS PERCEPTIONS OF PATIENTS BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA | Isabelle Vande Broek | ![]() |
![]() |
|||
1081-P | PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY | Fabio Efficace | ![]() |
![]() |
|||
1082-P | CROSS-CULTURAL DEVELOPMENT OF AN EORTC QUESTIONNAIRE FOR ASSESSING QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS: THE EORTC QLQ-CML24 | Fabio Efficace | ![]() |
![]() |
|||
1084-P | HOW ACCURATE ARE PHYSICIANS IN ESTIMATING SYMPTOM SEVERITY AND HEALTH STATUS OF THEIR CHRONIC MYELOID LEUKEMIA PATIENTS? | Fabio Efficace | ![]() |
![]() |
|||
1085-P | PATTERNS OF FATIGUE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER OBSERVATIONAL STUDY | Fabio Efficace | ![]() |
![]() |
|||
1086-P | PAIN AND EMOTIONAL DISTRESS IN HEMATOLOGIC PATIENTS THROUGHOUT ALL PHASES OF DISEASE: RESULTS FROM A MULTIDISCIPLINARY RESEARCH TEAM IN MODENA UNIVERSITY HOSPITAL | Pierluigi Alfieri | ![]() |
![]() |
|||
1087-P | EFFICACY OF FENTANYL IN COMPARISON TO KETAMINE IN ANALGESIC EFFECT FOR HEMATOLOGY /ONCOLOGY PROCEDURES IN CHILDREN. A RANDOMIZED, DOUBLE-BLINDED, CROSSOVER, PLACEBO-CONTROLLED TRIAL | chanchai traivaree | ![]() |
![]() |
|||
1088-P | IS SCREENING FOR MALNUTRITION USEFUL IN OLDER PATIENTS WITH AGGRESSIVE HAEMATOLOGICAL MALIGNANCIES? | Anja Velghe | ![]() |
![]() |
|||
1089-P | IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN ACUTE MYELOID LEUKEMIA SURVIVORS | Annemieke Leunis | ![]() |
![]() |
|||
1090-P | VALIDATION OF THE G8 IN OLDER PATIENTS WITH A HAEMATOLOGICAL MALIGNANCY | Anja Velghe | ![]() |
![]() |
|||
1091-P | PSYCHOLOGICAL ASSESSMENT OF SIBLINGS OF PATIENTS WITH CHILDHOOD CANCER: A FORGOTTEN GROUP | Ragab Iman | ![]() |
![]() |
|||
1092-P | HEALTH-RELATED QUALITY OF LIFE AMONG LONG-TERM SURVIVORS OF ADOLESCENT HODGKINS LYMPHOMA TREATED WITH PEDIATRIC APPROACH | Sergey Semochkin | ![]() |
![]() |
|||
1094-P | EARLY SUPPORTIVE/PALLIATIVE CARE INTEGRATED WITH STANDARD HEMATOLOGICAL CARE (SIMULTANEOUS CARE) IN MULTIPLE MYELOMA PATIENTS | FEDERICO VINCENZO | ![]() |
![]() |
|||
1095-P | WHAT DO PRELIMINARY ANALYSES HIGHLIGHT AS THE KEY FEARS AND WORRIES OF CHILDREN AND YOUNG PEOPLE WITH SICKLE CELL DISEASE AND WHAT CAN WE DO TO SUPPORT THEM? | Florence Bristow | ![]() |
![]() |
|||
1096-P | COMPREHENSIVE ANALYSIS OF CLINICALLY RELEVANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN HEMATOLOGIC MALIGNANCY FROM THE VIEWPOINT OF REVISED EMAS GUIDELINE ON ANTICANCER MEDICINAL PRODUCTS | Sumimasa Nagai | ![]() |
![]() |
|||
1097-P | DOES PREGNANCY INFLUENCE REMISSION RATE IN HEMATOLOGICAL MALIGNANCIES | Maria Vinogradova | ![]() |
![]() |
|||
1098-P | VALIDATION OF A COMPREHENSIVE HEALTH STATUS ASSESSMENT SCALE IN OLDER PATIENTS (= 65 YEARS) WITH HEMATOLOGICAL MALIGNANCES. GAH STUDY | Cristina Romera | ![]() |
![]() |
|||
1099-P | PSYCHOLOGICAL MORBIDITY FOLLOWING THE DIAGNOSIS OF A HAEMATOLOGICAL MALIGNANCY | Barry Kevane | ![]() |
![]() |
|||
1100-P | QUALITY OF LIFE OF THE PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | LIUDMILA GRITSAY | ![]() |
![]() |
13-16 June 2013 STOCKHOLM
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
![]() ![]() |